Clinical Pharmacokinetics and Pharmacodynamics of T
Transplantation

Clinical Pharmacokinetics

43, 623-653

DOI: 10.2165/00003088-200443100-00001

Citation Report

#	Article	IF	Citations
1	Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplant patients. Clinical Pharmacology and Therapeutics, 2005, 78, 168-181.	2.3	75
2	Guidelines for the treatment and management of new-onset diabetes after transplantation1.. Clinical Transplantation, 2005, 19, 291-298.	0.8	228
3	Co-transplantation of autologous adult stem cells together with differentiated derivatives of human embryonic stem cells. A novel strategy to enhance the efficacy of autologous cell-transplantation therapy?. Wound Repair and Regeneration, 2005, 13, 353-356.	1.5	0
4	Immunosuppressants: Pharmacokinetics, methods of monitoring and role of high performance liquid chromatography/mass spectrometry. Clinical and Applied Immunology Reviews, 2005, 5, 405-430.	0.4	24
6	Tacrolimus Pharmacokinetics and Dose Monitoring After Lung Transplantation for Cystic Fibrosis and Other Conditions. American Journal of Transplantation, 2005, 5, 1477-1482.	2.6	39
8	Distinct Inhibitory Effects of Tacrolimus and Cyclosporin A on Calcineurin Phosphatase Activity. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 816-825.	1.3	38
9	The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression?. Pharmacogenomics, 2005, 6, 323-337.	0.6	82
10	Immunosuppressant Drug Monitoring: Is the Laboratory Meeting Clinical Expectations?. Annals of Pharmacotherapy, 2005, 39, 119-127.	0.9	25
11	Cyclosporin But Not Tacrolimus Significantly Increases Salivary Cytokine Contents in Rats. Journal of Periodontology, 2005, 76, 1520-1525.	1.7	12
12	New Strategies in Immunosuppression. Transplantation Proceedings, 2005, 37, 2675-2678.	0.3	18
13	Pharmacokinetic Study of Tacrolimus in Cystic Fibrosis and Non-Cystic Fibrosis Lung Transplant Patients and Design of Bayesian Estimators Using Limited Sampling Strategies. Clinical Pharmacokinetics, 2005, 44, 1317-1328.	1.6	50
14	Tacrolimus. Drugs, 2005, 65, 993-1001.	4.9	16
15	Pharmacokinetic Considerations Relating to Tacrolimus Dosing in the Elderly. Drugs and Aging, 2005, 22, 541-557.	1.3	56
16	Tacrolimus. Drugs, 2006, 66, 2269-2279.	4.9	23
17	Clinical pharmacokinetics of voriconazole. International Journal of Antimicrobial Agents, 2006, 27, 274-284.	1.1	129
18	Breastfeeding During Tacrolimus Therapy. Obstetrics and Gynecology, 2006, 107, 453-455.	1.2	60
19	Active Drug Transport of Immunosuppressants. Therapeutic Drug Monitoring, 2006, 28, 39-44.	1.0	77
20	Buccal vs. nasogastric tube administration of tacrolimus after pediatric liver transplantation. Pediatric Transplantation, 2006, 10, 74-77.	0.5	19

#	Article	IF	Citations
21	Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. Clinical Pharmacology and Therapeutics, 2006, 80, 331-345.	2.3	93
22	Delayed Effect of Grapefruit Juice on Pharmacokinetics and Pharmacodynamics of Tacrolimus in a Living-Donor Liver Transplant Recipient. Drug Metabolism and Pharmacokinetics, 2006, 21, 122-125.	1.1	35
23	Temporal Decline in Sirolimus Elimination Immediately After Pancreatic Islet Transplantation. Drug Metabolism and Pharmacokinetics, 2006, 21, 492-500.	1.1	5
25	Topical Calcineurin Inhibitors for Atopic Dermatitis. Archives of Dermatology, 2006, 142, 633-7.	1.7	44
26	Influence of different allelic variants of theCYP3AandABCB1genes on the tacrolimus pharmacokinetic profile of Chinese renal transplant recipients. Pharmacogenomics, 2006, 7, 563-574.	0.6	39
27	Tacrolimus in rheumatoid arthritis. Expert Opinion on Pharmacotherapy, 2006, 7, 91-98.	0.9	18
28	Metabolism of Tacrolimus (FK506) and Recent Topics in Clinical Pharmacokinetics. Drug Metabolism and Pharmacokinetics, 2007, 22, 328-335.	1.1	203
29	Analysis of Factors Influencing Tacrolimus Levels and Immunoassay Bias in Renal Transplantation. Journal of Clinical Pharmacology, 2007, 47, 1035-1042.	1.0	8
31	Validation of a Liquid Chromatography-Mass Spectrometric Assay for Tacrolimus in Liver Biopsies After Hepatic Transplantation: Correlation With Histopathologic Staging of Rejection. Therapeutic Drug Monitoring, 2007, 29, 340-348.	1.0	56
32	Tacrolimus in Diabetic Kidney Transplant Recipients: Pharmacokinetics and Application of a Limited Sampling Strategy. Therapeutic Drug Monitoring, 2007, 29, 391-398.	1.0	24
33	Dried Blood Spot Measurement of Tacrolimus Is Promising for Patient Monitoring. Transplantation, 2007, 83, 237-238.	0.5	55
34	Causes of Rehospitalization After Renal Transplantation; Does Age of Recipient Matter?. Transplantation Proceedings, 2007, 39, 970-973.	0.3	5
35	Acute inhibition of calcineurin restores associative learning and memory in Tg2576 APP transgenic mice. Neurobiology of Learning and Memory, 2007, 88, 217-224.	1.0	135
36	Polymorphisms of tumor necrosis factor-Î±, interleukin-10, cytochrome P450 3A5 and ABCB1 in Chinese liver transplant patients treated with immunosuppressant tacrolimus. Clinica Chimica Acta, 2007, 383, 133-139.	0.5	36
37	38 Drugs that act on the immune system: immunosuppressive and immunostimulatory drugs. Side Effects of Drugs Annual, 2007, , 424-479.	0.6	1
38	The use of tacrolimus in the treatment of inflammatory bowel disease. Expert Opinion on Drug Safety, 2007, 6, 479-485.	1.0	26
39	Next-generation calcineurin inhibitors for ophthalmic indications. Expert Opinion on Investigational Drugs, 2007, 16, 1525-1540.	1.9	31
40	Effect of Highly Active AntiretroviralÂTherapyÂon TacrolimusÂPharmacokinetics inÂHepatitisÂCÂVirusÂandÂHIV Co-InfectedÂLiverÂTransplant Recipients in the ANRS HC-08 Study. Clinical Pharmacokinetics, 2007, 46, 941-952.	1.6	56

#	Article	IF	Citations
41	Tacrolimus Once-Daily Formulation. Drugs, 2007, 67, 1931-1943.	4.9	44
42	CYP3A5 and CYP3A4 but not MDR1 Single-nucleotide Polymorphisms Determine Long-term Tacrolimus Disposition and Drug-related Nephrotoxicity in Renal Recipients. Clinical Pharmacology and Therapeutics, 2007, 82, 711-725.	2.3	192
43	Dried blood spot measurement: application in tacrolimus monitoring using limited sampling strategy and abbreviated AUC estimation. Transplant International, 2007, 21, 071017161014001-???.	0.8	59
44	Cyclosporine pharmacokinetics and blood pressure responses after conversion to once-daily dosing in maintenance liver transplant patients. Clinical Transplantation, 2007, 22, 070806210014001-???.	0.8	5
45	Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients. Journal of Clinical Pharmacy and Therapeutics, 2007, 32, 505-515.	0.7	65
46	Circadian and time-dependent variability in tacrolimus pharmacokinetics. Fundamental and Clinical Pharmacology, 2007, 21, 191-197.	1.0	50
47	Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphateâ€binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms. Fundamental and Clinical Pharmacology, 2007, 21, 427-435.	1.0	78
49	Evaluation of limited sampling strategies for tacrolimus. European Journal of Clinical Pharmacology, 2007, 63, 1039-1044.	0.8	25
50	Pharmacokinetics of Cyclosporine A After Massive Hepatectomy: A Hint for Small-for-Size Graft in Living Donor Liver Transplantation. Digestive Diseases and Sciences, 2007, 52, 2490-2496.	1.1	3
51	Therapeutic drug monitoring of tacrolimus with the dried blood spot method. Journal of Pharmaceutical and Biomedical Analysis, 2007, 44, 658-664.	1.4	165
52	Design and Evaluation of Self-Microemulsifying Drug Delivery System (SMEDDS) of Tacrolimus. AAPS PharmSciTech, 2008, 9, 13-21.	1.5	100
53	An objective measure to identify pediatric liver transplant recipients at risk for late allograft rejection related to nonâ€adherence. Pediatric Transplantation, 2008, 12, 67-72.	0.5	83
54	Sublingual administration of tacrolimus in a renal transplant patient. Journal of Clinical Pharmacy and Therapeutics, 2008, 33, 87-89.	0.7	20
55	Corticosteroid Interactions with Cyclosporine, Tacrolimus, Mycophenolate, and Sirolimus: Fact or Fiction?. Annals of Pharmacotherapy, 2008, 42, 1037-1047.	0.9	86
56	Effect of aprepitant on intravenous tacrolimus disposition in reduced intensity hematopoietic stem cell transplantation. Journal of Oncology Pharmacy Practice, 2008, 14, 113-121.	0.5	8
57	Pharmacodynamic Monitoring of Calcineurin Phosphatase Activity in Transplant Patients Treated with Calcineurin Inhibitors. Drug Metabolism and Pharmacokinetics, 2008, 23, 150-157.	1.1	36
58	Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenetics and Genomics, 2008, 18, 413-423.	0.7	91
59	Limited Sampling Strategy for Simultaneous Estimation of the Area Under the Concentration-Time Curve of Tacrolimus and Mycophenolic Acid in Adult Renal Transplant Recipients. Therapeutic Drug Monitoring, 2008, 30, 52-59.	1.0	46

#	Article	IF	Citations
60	Maturation of Dose-Corrected Tacrolimus Predose Trough Levels in Pediatric Kidney Allograft Recipients. Transplantation, 2008, 85, 1139-1145.	0.5	38
61	A new agent for the treatment of noninfectious uveitis: rationale and design of three LUMINATE (Lux) Tj ETQq1 1 0.784314 rgBT /Overlock voclosporin. Clinical Ophthalmology, 2008, 2, 693.	0.9	23
62	Flexible Limited Sampling Model for Monitoring Tacrolimus in Stable Patients Having Undergone Liver Transplantation With Samples 4 to 6 Hours After Dosing Is Superior to Trough Concentration. Therapeutic Drug Monitoring, 2008, 30, 456-461.	1.0	17
63	Prospective Evaluation of the Bayesian Method for Individualizing Tacrolimus Dose Early After Livingâ€Donor Liver Transplantation. Journal of Clinical Pharmacology, 2009, 49, 789-797.	1.0	20
64	Donor Age and Renal P-Glycoprotein Expression Associate with Chronic Histological Damage in Renal Allografts. Journal of the American Society of Nephrology: JASN, 2009, 20, 2468-2480.	3.0	126
65	Pharmacokinetics for Once- Versus Twice-Daily Tacrolimus Formulations in De Novo Kidney Transplantation: A Randomized, Open-Label Trial. American Journal of Transplantation, 2009, 9, 2505-2513.	2.6	110
66	Chromosomal aberrations in UVBâ€induced tumors of immunosuppressed mice. Genes Chromosomes and Cancer, 2009, 48, 490-501.	1.5	5
67	Study of the effect of Wuzhi tablet (Schisandra sphenanthera extract) on tacrolimus tissue distribution in rat by liquid chromatography tandem mass spectrometry method. Biomedical Chromatography, 2010, 24, 399-405.	0.8	38
68	Optimal Administration of Tacrolimus in Reduced-Size Liver. Digestive Diseases and Sciences, 2009, 54, 1789-1793.	1.1	1
69	Change in blood tacrolimus concentration by fluctuation of renal function in a bone marrow transplant patient. European Journal of Drug Metabolism and Pharmacokinetics, 2009, 34, 201-204.	0.6	2
70	Co-administration of grapefruit juice increases bioavailability of tacrolimus in liver transplant patients: a prospective study. European Journal of Clinical Pharmacology, 2009, 65, 881-885.	0.8	59
71	Evaluation of risk factor management of patients treated on an internal nephrology ward: a pilot study. BMC Clinical Pharmacology, 2009, 9, 15.	2.5	2
72	Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant. British Journal of Clinical Pharmacology, 2009, 68, 413-421.	1.1	53
73	Population Pharmacokinetics and Pharmacogenetics of Tacrolimus in De Novo Pediatric Kidney Transplant Recipients. Clinical Pharmacology and Therapeutics, 2009, 86, 609-618.	2.3	142
74	Tacrolimus pharmacokinetic drug interactions: effect of prednisone, mycophenolic acid or sirolimus. Fundamental and Clinical Pharmacology, 2009, 23, 137-145.	1.0	30
75	Heterophilic antibody interference in a non-endogenous molecule assay: An apparent elevation in the tacrolimus concentration. Clinica Chimica Acta, 2009, 402, 193-195.	0.5	35
76	Pharmacokinetic Optimization of Immunosuppressive Therapy in Thoracic Transplantation: Part I. Clinical Pharmacokinetics, 2009, 48, 419-462.	1.6	55
77	Development and Characterization of Self-Microemulsifying Drug Delivery System of Tacrolimus for Intravenous Administration. Drug Development and Industrial Pharmacy, 2009, 35, 619-630.	0.9	21

#	Article	IF	Citations
78	Immunotherapy in Elderly Transplant Recipients. Drugs and Aging, 2009, 26, 715-737.	1.3	68
79	Tacrolimus Ameliorates Metabolic Disturbance and Oxidative Stress Caused by Hepatitis C Virus Core Protein. American Journal of Pathology, 2009, 175, 1515-1524.	1.9	9
80	Calcineurin Inhibitor Nephrotoxicity. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 481-508.	2.2	1,178
81	Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference. Therapeutic Drug Monitoring, 2009, 31, 139-152.	1.0	398
82	Explaining Variability in Tacrolimus Pharmacokinetics to Optimize Early Exposure in Adult Kidney Transplant Recipients. Therapeutic Drug Monitoring, 2009, 31, 187-197.	1.0	119
83	Tacrolimus Concentrations in Relation to CYP3A and ABCB1 Polymorphisms Among Solid Organ Transplant Recipients in Korea. Transplantation, 2009, 87, 1225-1231.	0.5	42
84	New Insights Into the Pharmacokinetics and Pharmacodynamics of the Calcineurin Inhibitors and Mycophenolic Acid: Possible Consequences for Therapeutic Drug Monitoring in Solid Organ Transplantation. Therapeutic Drug Monitoring, 2009, 31, 416-435.	1.0	146
85	Tacrolimus: Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics to Facilitate Practitioners' Understanding and Offer Strategies for Educating Patients and Promoting Adherence. Progress in Transplantation, 2009, 19, 277-284.	0.4	45
86	Time of Drug Administration, CYP3A5 and ABCB1 Genotypes, and Analytical Method Influence Tacrolimus Pharmacokinetics: A Population Pharmacokinetic Study. Therapeutic Drug Monitoring, 2009, 31, 734-742.	1.0	29
87	Population Pharmacokinetics of Tacrolimus in Pediatric Hematopoietic Stem Cell Transplant Recipients: New Initial Dosage Suggestions and a Model-Based Dosage Adjustment Tool. Therapeutic Drug Monitoring, 2009, 31, 457-466.	1.0	38
88	Validation of a Liquid Chromatography-Mass Spectrometric Assay for Tacrolimus in Peripheral Blood Mononuclear Cells. Therapeutic Drug Monitoring, 2009, 31, 178-186.	1.0	54
89	CYP3A5 *1 Allele: Impacts on Early Acute Rejection and Graft Function in Tacrolimus-Based Renal Transplant Recipients. Transplantation, 2010, 90, 1394-1400.	0.5	52
90	A Systematic Review of the Effect of CYP3A5 Genotype on the Apparent Oral Clearance of Tacrolimus in Renal Transplant Recipients. Therapeutic Drug Monitoring, 2010, 32, 708-714.	1.0	65
91	Reduced C0 Concentrations and Increased Dose Requirements in Renal Allograft Recipients Converted to the Novel Once-Daily Tacrolimus Formulation. Transplantation, 2010, 90, 523-529.	0.5	72
92	A Transient Increase of Calcineurin Phosphatase Activity in Living-Donor Kidney Transplant Recipients with Acute Rejection. Drug Metabolism and Pharmacokinetics, 2010, 25, 411-417.	1.1	19
93	Pharmacokinetics of Orally Administered Tacrolimus in Lupus Nephritis Patients. Yakugaku Zasshi, 2010, 130, 113-118.	0.0	5
94	Calcineurin inhibitor tacrolimus does not interfere with the suppression of hepatitis C virus infection by interferon-Î±. Liver Transplantation, 2010, 16, 520-526.	1.3	21
95	Mechanistic understanding of the different effects of Wuzhi Tablet (Schisandra sphenanthera) Tj ETQq1 1 0.784314 rgBT /Overlock 1 International Journal of Pharmaceutics, 2010, 389, 114-121.	2.6	89

#	Article	IF	Citations
96	Variability in tacrolimus blood levels increases the risk of late rejection and graft loss after solid organ transplantation in older children. Pediatric Transplantation, 2010, 14, 968-975.	0.5	149
97	The Impact of a Change in Tacrolimus Monitoring Immunoassay Techniques on Clinical Decision Making. Progress in Transplantation, 2010, 20, 350-356.	0.4	1
98	High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. Nephrology Dialysis Transplantation, 2010, 25, 2757-2763.	0.4	210
99	CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation. Pharmacogenomics, 2010, 11, 703-714.	0.6	97
100	Ranolazine-Tacrolimus Interaction. Annals of Pharmacotherapy, 2010, 44, 1844-1849.	0.9	11
101	Mechanisms behind Local Immunosuppression Using Inhaled Tacrolimus in Preclinical Models of Lung Transplantation. American Journal of Respiratory Cell and Molecular Biology, 2010, 43, 403-412.	1.4	21
102	Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation. Pharmacological Reports, 2010, 62, 1159-1169.	1.5	44
103	Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part I. Clinical Pharmacokinetics, 2010, 49, 141-175.	1.6	282
104	Evaluation of a New Immunoassay for Therapeutic Drug Monitoring of Tacrolimus in Adult Liver Transplant Recipients. Journal of Clinical Pharmacology, 2010, 50, 705-709.	1.0	9
105	Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitorsâ€™ dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics, 2011, 12, 1383-1396.	0.6	139
106	Pharmacology of Immunosuppressive Medications in Solid Organ Transplantation. Critical Care Nursing Clinics of North America, 2011, 23, 405-423.	0.4	4
107	Once- Versus Twice-Daily Tacrolimus. Drugs, 2011, 71, 1561-1577.	4.9	87
108	A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients. Clinical Chemistry, 2011, 57, 1574-1583.	1.5	211
109	Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients. Journal of Heart and Lung Transplantation, 2011, 30, 1352-1359.	0.3	81
110	Pathophysiological idiosyncrasies and pharmacokinetic realities may interfere with tacrolimus dose titration in liver transplantation. European Journal of Clinical Pharmacology, 2011, 67, 671-679.	0.8	3
111	Clinical Pharmacokinetics of Triple Immunosuppression Scheme in Kidney Transplant (Tacrolimus,) Tj ETQq1 1 0.784314 rgBT /Overlock 2		
112	Development and Evaluation of a Simulation Procedure to Take Into Account Various Assays for the Bayesian Dose Adjustment of Tacrolimus. Therapeutic Drug Monitoring, 2011, 33, 171-177.	1.0	18
113	Novel Polymorphisms Associated With Tacrolimus Trough Concentrations: Results From a Multicenter Kidney Transplant Consortium. Transplantation, 2011, 91, 300-308.	0.5	151

#	Article	IF	Citations
114	Expression of CYP3A5 and P-glycoprotein in Renal Allografts With Histological Signs of Calcineurin Inhibitor Nephrotoxicity. Transplantation, 2011, 91, 1098-1102.	0.5	37
115	Limited Sampling Strategies for Monitoring Tacrolimus in Pediatric Liver Transplant Recipients. Therapeutic Drug Monitoring, 2011, 33, 380-386.	1.0	14
116	Initial liver graft function is a reliable predictor of tacrolimus trough levels during the first postâ€transplant week. Clinical Transplantation, 2011, 25, 436-443.	0.8	15
117	Efficacy, safety, and immunosuppressant adherence in stable liver transplant patients converted from a twice-daily tacrolimus-based regimen to once-daily tacrolimus extended-release formulation. Transplant International, 2011, 24, 666-675.	0.8	108
118	Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1â€ƒyear after renal transplantation. Journal of Clinical Pharmacy and Therapeutics, 2011, 36, 208-216.	0.7	12
119	Evaluation of limited sampling methods for estimation of tacrolimus exposure in adult kidney transplant recipients. British Journal of Clinical Pharmacology, 2011, 71, 207-223.	1.1	43
120	Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations â€“ twice daily Prograf^{Â®} and once daily Advagraf^{Â®}. British Journal of Clinical Pharmacology, 2011, 71, 391-402.	1.1	93
121	Dosing equation for tacrolimus using genetic variants and clinical factors. British Journal of Clinical Pharmacology, 2011, 72, 948-957.	1.1	140
122	Drug Interactions Between the Immunosuppressant Tacrolimus and the Cholesterol Absorption Inhibitor Ezetimibe in Healthy Volunteers. Clinical Pharmacology and Therapeutics, 2011, 89, 524-528.	2.3	13
123	Interleukin-2 Profiles Shortly After Tacrolimus Conversion From a Twice-Daily to Once-Daily Regimen. Transplantation Proceedings, 2011, 43, 1017-1019.	0.3	3
124	Tacrolimus Trough Levels and Level-to-Dose Ratio in Stable Renal Transplant Patients Converted to a Once-Daily Regimen. Transplantation Proceedings, 2011, 43, 1024-1027.	0.3	7
125	Bioequivalence of Two Tacrolimus Formulations Under Fasting Conditions in Healthy Male Subjects. Clinical Therapeutics, 2011, 33, 1105-1119.	1.1	7
126	The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation. European Journal of Clinical Pharmacology, 2011, 67, 1231-1241.	0.8	62
127	Pharmacokinetics for once-daily versus twice-daily tacrolimus formulations in de novo liver transplantation: A randomized, open-label trial. Liver Transplantation, 2011, 17, 167-177.	1.3	51
128	Impact of ATP-binding cassette, subfamily B, member 1 pharmacogenetics on tacrolimus-associated nephrotoxicity and dosage requirements in paediatric patients with liver transplant. Expert Opinion on Drug Safety, 2011, 10, 9-22.	1.0	14
129	Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients. Pharmacogenomics, 2011, 12, 977-984.	0.6	69
130	In Vivo CYP3A Activity Is Significantly Lower in Cyclosporine-Treated as Compared With Tacrolimus-Treated Renal Allograft Recipients. Clinical Pharmacology and Therapeutics, 2011, 90, 414-422.	2.3	36
131	Population Pharmacokinetics of Tacrolimus in Pediatric Liver Transplantation: Early Posttransplantation Clearance. Therapeutic Drug Monitoring, 2011, 33, 663-672.	1.0	37

#	Article	IF	Citations
132	Managing the atazanavirâ€“tacrolimus drug interaction in a renal transplant recipient. American Journal of Health-System Pharmacy, 2011, 68, 138-142.	0.5	6
133	Population Pharmacokinetics and Pharmacogenetics of Tacrolimus in Healthy Chinese Volunteers. Pharmacology, 2011, 88, 288-294.	0.9	16
134	Pharmacokinetics of tacrolimus converted from twice-daily formulation to once-daily formulation in Chinese stable liver transplant recipients. Acta Pharmacologica Sinica, 2011, 32, 1419-1423.	2.8	6
135	Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective. Pharmacogenomics Journal, 2011, 11, 300-306.	0.9	48
136	Pharmacokinetics in Stable Kidney Transplant Recipients After Conversion From Twice-Daily to Once-daily Tacrolimus Formulations. Therapeutic Drug Monitoring, 2012, 34, 46-52.	1.0	44
137	Tacrolimus Pharmacokinetics of Once- Versus Twice-Daily Formulations in De Novo Kidney Transplantation. Therapeutic Drug Monitoring, 2012, 34, 143-147.	1.0	23
138	The Impact of Sulfonylureas on Tacrolimus Apparent Clearance Revealed by a Population Pharmacokinetics Analysis in Chinese Adult Liver-Transplant Patients. Therapeutic Drug Monitoring, 2012, 34, 126-133.	1.0	24
139	A Simultaneous Dâ€Optimal Designed Study for Population Pharmacokinetic Analyses of Mycophenolic Acid and Tacrolimus Early After Renal Transplantation. Journal of Clinical Pharmacology, 2012, 52, 1833-1843.	1.0	35
140	Pharmacokinetics of tacrolimus and mycophenolate mofetil in renal transplant recipients on a corticosteroid-free regimen. American Journal of Health-System Pharmacy, 2012, 69, 134-142.	0.5	9
141	Impact of Tacrolimus Intraindividual Variability and CYP3A5 Genetic Polymorphism on Acute Rejection in Kidney Transplantation. Therapeutic Drug Monitoring, 2012, 34, 680-685.	1.0	61
142	Effect of Mild Diarrhea on Tacrolimus Exposure. Transplantation, 2012, 94, 763-767.	0.5	15
143	Comparison of Pharmacokinetics and Pharmacogenetics of Once- and Twice-Daily Tacrolimus in the Early Stage After Renal Transplantation. Transplantation, 2012, 94, 1013-1019.	0.5	55
144	The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients. Pharmacogenetics and Genomics, 2012, 22, 32-42.	0.7	89
145	Generic Tacrolimus in Renal Transplantation. Transplantation, 2012, 93, e45-e46.	0.5	9
146	NR1I2 Polymorphisms Are Related to Tacrolimus Dose-Adjusted Exposure and BK Viremia in Adult Kidney Transplantation. Transplantation, 2012, 94, 1025-1032.	0.5	44
147	The effect of CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients. Pharmacogenetics and Genomics, 2012, 22, 642-645.	0.7	61
148	Corticosteroids in recurrence of glomerular disease in renal transplantation: Do we know the right questions to ask?. Pediatric Transplantation, 2012, 16, 684-687.	0.5	0
149	Kidney transplant outcomes are related to tacrolimus, mycophenolic acid and prednisolone exposure in the first week. Transplant International, 2012, 25, 1182-1193.	0.8	35

#	Article	IF	Citations
150	CYP3A5 Polymorphism in Mexican Renal Transplant Recipients and its Association with Tacrolimus Dosing. Archives of Medical Research, 2012, 43, 283-287.	1.5	37
151	Impact of Glomerular Kidney Diseases on the Clearance of Drugs. Journal of Clinical Pharmacology, 2012, 52, 23S-34S.	1.0	12
152	DETERMINATION OF FK506 IN RAT BLOOD BY LC-MS/MS AND EFFECT OF SILYMARIN ON ITS PHARMACOKINETICS. Journal of Liquid Chromatography and Related Technologies, 2012, 35, 2217-2227.	0.5	2
153	Validation of tacrolimus equation to predict troughs using genetic and clinical factors. Pharmacogenomics, 2012, 13, 1141-1147.	0.6	32
154	In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Hematocrit Predict Tacrolimus Dose Requirements and Clearance in Renal Transplant Patients. Clinical Pharmacology and Therapeutics, 2012, 92, 366-375.	2.3	100
155	Use of sublingual tacrolimus in lung transplant recipients. Journal of Heart and Lung Transplantation, 2012, 31, 127-132.	0.3	22
156	Simultaneous measurement of cyclosporin A and tacrolimus from dried blood spots by ultra high performance liquid chromatography tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 883-884, 102-107.	1.2	58
157	Successful and cost-efficient replacement of immunoassays by tandem mass spectrometry for the quantification of immunosuppressants in the clinical laboratory. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 883-884, 95-101.	1.2	24
158	Optimization of the use of Calcineurin inhibitors in liver transplantation. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2012, 26, 85-95.	1.0	25
159	Tacrolimus trough levels before, during and after jejunostomy in a liver transplant patient: A case report. Clinics and Research in Hepatology and Gastroenterology, 2012, 36, e126-e130.	0.7	3
160	Drug Interaction Between Tacrolimus and Ertapenem in Renal Transplantation Recipients. Transplantation Proceedings, 2012, 44, 3029-3032.	0.3	7
161	Measurement and Compartmental Modeling of the Effect of CYP3A5 Gene Variation on Systemic and Intrarenal Tacrolimus Disposition. Clinical Pharmacology and Therapeutics, 2012, 92, 737-745.	2.3	46
162	Multicenter Clinical Investigation for the Safety and Efficacy of AdvagrafÂ® (Extended Release) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 27 Transplantation: Preliminary Results. The Journal of the Korean Society for Transplantation, 2012, 26, 254.	0.2	0
163	Beneficial Pharmacokinetic Drug Interactions. Advances in Pharmacoepidemiology & Drug Safety, 2012, 01, .	0.1	5
164	Individualized immunosuppression in transplant patients: potential role of pharmacogenetics. Pharmacogenomics and Personalized Medicine, 2012, 5, 63.	0.4	11
165	The interactions of age, sex, body mass index, genetics, and steroid weight-based doses on tacrolimus dosing requirement after adult kidney transplantation. European Journal of Clinical Pharmacology, 2012, 68, 671-680.	0.8	70
166	Correlation of tacrolimus levels in peripheral blood mononuclear cells with histological staging of rejection after liver transplantation: preliminary results of a prospective study. Transplant International, 2012, 25, 41-47.	0.8	92
167	A Randomized Pharmacokinetic Study of Generic Tacrolimus Versus Reference Tacrolimus in Kidney Transplant Recipients. American Journal of Transplantation, 2012, 12, 2825-2831.	2.6	58

#	Article	IF	Citations
168	A clinically significant interaction between tacrolimus and multiple proton pump inhibitors in a kidney transplant recipient. Pediatric Transplantation, 2012, 16, E217-20.	0.5	23
169	Intraâ€patient variability in tacrolimus trough concentrations and renal function decline in pediatric renal transplant recipients. Pediatric Transplantation, 2012, 16, 613-618.	0.5	38
170	Tacrolimus pharmacokinetics in the early post-liver transplantation period and clinical applicability via Bayesian prediction. European Journal of Clinical Pharmacology, 2013, 69, 65-74.	0.8	30
171	Pharmaceutical and genetic determinants for interindividual differences of tacrolimus bioavailability in renal transplant recipients. European Journal of Clinical Pharmacology, 2013, 69, 1659-1665.	0.8	26
172	Population pharmacokinetic analysis of tacrolimus in the first year after pediatric liver transplantation. European Journal of Clinical Pharmacology, 2013, 69, 1533-1542.	0.8	29
173	Effect of itraconazole on the concentrations of tacrolimus and cyclosporine in the blood of patients receiving allogeneic hematopoietic stem cell transplants. European Journal of Clinical Pharmacology, 2013, 69, 1321-1329.	0.8	30
174	The evaluation of potential pharmacokinetic interaction between sirolimus and tacrolimus in healthy volunteers. European Journal of Clinical Pharmacology, 2013, 69, 835-842.	0.8	9
175	Multidrug Resistance-Associated Protein 2 (MRP2/ABCC2) Haplotypes Significantly Affect the Pharmacokinetics of Tacrolimus in Kidney Transplant Recipients. Clinical Pharmacokinetics, 2013, 52, 751-762.	1.6	68
176	Effects of Traditional Chinese Medicine Wuzhi Capsule on Pharmacokinetics of Tacrolimus in Rats. Drug Metabolism and Disposition, 2013, 41, 1398-1403.	1.7	54
177	Effect of long-term co-administration of Wuzhi tablet (Schisandra sphenanthera extract) and prednisone on the pharmacokinetics of tacrolimus. Phytomedicine, 2013, 20, 375-379.	2.3	37
178	Genetic Differences in Native Americans and Tacrolimus Dosing After Kidney Transplantation. Transplantation Proceedings, 2013, 45, 137-141.	0.3	16
179	Effect of amlodipine on the pharmacokinetics of tacrolimus in rats. Xenobiotica, 2013, 43, 699-704.	0.5	10
180	Inclusion of <scp>CYP</scp> 3 <scp>A</scp> 5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation. Transplant International, 2013, 26, 1198-1207.	0.8	60
181	Sublingual Tacrolimus: A Pharmacokinetic Evaluation Pilot Study. Pharmacotherapy, 2013, 33, 31-37.	1.2	22
182	DNA binding activity of nuclear factor of activated T cells in mononuclear cells from renal transplant patients with and without BK virus viruria. Tzu Chi Medical Journal, 2013, 25, 112-116.	0.4	1
183	Monitoring of tacrolimus concentrations in peripheral blood mononuclear cells: Application to cardiac transplant recipients. Clinical Biochemistry, 2013, 46, 1538-1541.	0.8	50
184	Effective long-term immunosuppression in rats by subcutaneously implanted sustained-release tacrolimus pellet: Effect on spinally grafted human neural precursor survival. Experimental Neurology, 2013, 248, 85-99.	2.0	24
185	Concentration of tacrolimus and major metabolites in kidney transplant recipients as a function of diabetes mellitus and cytochrome P450 3A gene polymorphism. Xenobiotica, 2013, 43, 641-649.	0.5	19

#	Article	IF	Citations
186	Pharmacokinetics of a self-microemulsifying drug delivery system of tacrolimus. Biomedicine and Pharmacotherapy, 2013, 67, 469-473.	2.5	10
187	Nuclear translocation of nuclear factor of activated T cells (NFAT) as a quantitative pharmacodynamic parameter for tacrolimus. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2013, 83, 1096-1104.	1.1	45
188	A Markov Chain Model to Evaluate the Effect of CYP3A5 and ABCB1 Polymorphisms on Adverse Events Associated with Tacrolimus in Pediatric Renal Transplantation. AAPS Journal, 2013, 15, 1189-1199.	2.2	13
189	Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients. European Journal of Clinical Pharmacology, 2013, 69, 53-63.	0.8	62
190	Effect of CYP3A5*3 Polymorphism on Pharmacokinetic Drug Interaction between Tacrolimus and Amlodipine. Drug Metabolism and Pharmacokinetics, 2013, 28, 398-405.	1.1	22
191	Lessons From Routine Dose Adjustment of Tacrolimus in Renal Transplant Patients Based on Global Exposure. Therapeutic Drug Monitoring, 2013, 35, 322-327.	1.0	58
192	A Limited Sampling Strategy to Estimate the Area Under the Concentration-Time Curve of Tacrolimus Modified-release Once-daily Preparation in Renal Transplant Recipients. Therapeutic Drug Monitoring, 2013, 35, 228-232.	1.0	13
193	PharmGKB summary. Pharmacogenetics and Genomics, 2013, 23, 563-585.	0.7	184
194	Immunosuppression for the non-transplant physician: what should you know?. Breathe, 2013, 9, 202-208.	0.6	3
195	A Differential Impact of Mycophenolic Acid, Prednisolone, and Tacrolimus Exposure on sCD30 Levels in Adult Kidney Transplant Recipients. Therapeutic Drug Monitoring, 2013, 35, 240-245.	1.0	3
196	Treatment of Acute Tacrolimus Toxicity with Phenytoin in Solid Organ Transplant Recipients. Case Reports in Transplantation, 2013, 2013, 1-6.	0.1	17
197	Manic-Like Psychosis Associated with Elevated Trough Tacrolimus Blood Concentrations 17 Years after Kidney Transplant. Case Reports in Psychiatry, 2013, 2013, 1-3.	0.2	15
198	A randomized, crossover pharmacokinetic study comparing generic tacrolimus vs. the reference formulation in subpopulations of kidney transplant patients. Clinical Transplantation, 2013, 27, E685-93.	0.8	15
199	Statistical tools for dose individualization of mycophenolic acid and tacrolimus coâ€administered during the first month after renal transplantation. British Journal of Clinical Pharmacology, 2013, 75, 1277-1288.	1.1	25
200	Significant reduction of Tacrolimus trough level after conversion from twice daily Prograf to once daily Advagraf in Chinese renal transplant recipients with or without concomitant diltiazem treatment. Renal Failure, 2013, 35, 942-945.	0.8	9
201	Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism â€“ a prospective, randomized, controlled study. Clinical Transplantation, 2013, 27, E272-81.	0.8	38
202	Therapeutic equivalence and pharmacokinetics of generic tacrolimus formulation in de novo kidney transplant patients. Nephrology Dialysis Transplantation, 2013, 28, 3110-3119.	0.4	23
203	Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients. Pharmacogenetics and Genomics, 2013, 23, 251-261.	0.7	103

#	Article	IF	Citations
204	Hepatic veno-occlusive disease resulting in tacrolimus toxicity after allogeneic hematopoietic stem cell transplantation. Blood Research, 2013, 48, 55.	0.5	8
205	Novel Single Nucleotide Polymorphisms in Interleukin 6 Affect Tacrolimus Metabolism in Liver Transplant Patients. PLoS ONE, 2013, 8, e73405.	1.1	18
206	Tacrolimus Does Not Affect Early Wound Healing in a Rodent Model of Bowel Anastomoses and Abdominal Wall Closure. PLoS ONE, 2013, 8, e76348.	1.1	3
207	Clinical Pharmacology and Therapeutic Drug Monitoring of Immunosuppressive Agents. , 2013, , .		1
208	Decreased Tacrolimus Levels after Administration of Rifampin to a Patient with Renal Transplant. Canadian Journal of Hospital Pharmacy, 2013, 66, 388-92.	0.1	9
209	Budget impact of switching from an immediate-release to a prolonged-release formulation of tacrolimus in renal transplant recipients in the UK based on differences in adherence. Patient Preference and Adherence, 2014, 8, 391.	0.8	15
210	The Population Pharmacokinetic Models of Tacrolimus in Chinese Adult Liver Transplantation Patients. Journal of Pharmaceutics, 2014, 2014, 1-7.	4.6	11
211	Ischemic-Type Biliary Lesions (ITBLs) after Liver Transplantation is associated with High Expression of CYP3A5 rs776746 Allele A and the Immunilogical Therapeutic Mechanisms of Medicine. Internal Medicine: Open Access, 2014, 04, .	0.0	0
212	Next-generation calcineurin inhibitors in development for the prevention of organ rejection. Transplant Research and Risk Management, 0, , 23.	0.7	0
213	Therapeutic drug monitoring of ciclosporin A and tacrolimus in heart lung transplant patients using dried blood spots. Annals of Clinical Biochemistry, 2014, 51, 106-109.	0.8	37
215	Sublingual Administration of Tacrolimus: Current Trends and Available Evidence. Pharmacotherapy, 2014, 34, 1209-1219.	1.2	24
216	Association of Hemoglobin Levels, CYP3A5, and NR1I3 Gene Polymorphisms with Tacrolimus Pharmacokinetics in Liver Transplant Patients. Drug Metabolism and Pharmacokinetics, 2014, 29, 249-253.	1.1	24
217	Once-daily LCP-Tacro MeltDose tacrolimus for the prophylaxis of organ rejection in kidney and liver transplantations. Expert Review of Clinical Immunology, 2014, 10, 1567-1579.	1.3	34
218	Population pharmacokinetic and pharmacogenetic analysis of tacrolimus in paediatric liver transplant patients. British Journal of Clinical Pharmacology, 2014, 77, 130-140.	1.1	38
219	Use of Graft-Derived Cell-Free DNA as an Organ Integrity Biomarker to Reexamine Effective Tacrolimus Trough Concentrations After Liver Transplantation. Therapeutic Drug Monitoring, 2014, 36, 136-140.	1.0	44
220	Effects of Combinational CYP3A5 6986A>G Polymorphism in Graft Liver and Native Intestine on the Pharmacokinetics of Tacrolimus in Liver Transplant Patients. Therapeutic Drug Monitoring, 2014, 36, 442-447.	1.0	23
221	Genetic variance in ABCB1 and CYP3A5 does not contribute toward the development of chronic kidney disease after liver transplantation. Pharmacogenetics and Genomics, 2014, 24, 427-435.	0.7	10
222	Population Pharmacokinetics of Tacrolimus in Adult Kidney Transplant Patients. Therapeutic Drug Monitoring, 2014, 36, 62-70.	1.0	70

#	Article	IF	Citations
223	De novo use of generic tacrolimus in liver transplantation â€“ a single center experience with oneâ€yr followâ€up. Clinical Transplantation, 2014, 28, 1349-1357.	0.8	10
224	Population Pharmacokinetic Analysis of Tacrolimus Early After Pediatric Liver Transplantation. Therapeutic Drug Monitoring, 2014, 36, 54-61.	1.0	24
225	Influence of Cytochrome P450 3A5 Polymorphisms on Viral Infection Incidence in Kidney Transplant Patients Treated With Tacrolimus. Transplantation Proceedings, 2014, 46, 570-573.	0.3	3
226	Conversion from twice- to once-daily tacrolimus in pediatric kidney recipients: a pharmacokinetic and bioequivalence study. Pediatric Nephrology, 2014, 29, 1081-1088.	0.9	15
227	The influence of comedication on tacrolimus blood concentration in patients subjected to kidney transplantation: a retrospective study. European Journal of Drug Metabolism and Pharmacokinetics, 2014, 39, 243-253.	0.6	12
228	Mechanisms of Immunosuppressive Drugs. , 2014, , 127-141.		2
229	Determination of the Most Influential Sources of Variability in Tacrolimus Trough Blood Concentrations in Adult Liver Transplant Recipients: A Bottom-Up Approach. AAPS Journal, 2014, 16, 379-391.	2.2	37
230	In Vivo to In Vitro Effects of Six Bioactive Lignans of Wuzhi Tablet (Schisandra Sphenanthera) Tj ETQq1 1 0.784314 rgBT /Overlock 1 Metabolism and Disposition, 2014, 42, 193-199.	1.7	51
231	Chemometric Methods for the Quantification of Crystalline Tacrolimus in Solid Dispersion by Powder Xâ€Ray Diffractrometry. Journal of Pharmaceutical Sciences, 2014, 103, 2819-2828.	1.6	27
232	Effect of Tacrolimus on the pharmacokinetics of bioactive lignans of Wuzhi tablet (Schisandra) Tj ETQq1 1 0.784314 rgBT /Overlock 10	2.3	50
233	The Role of Pharmacogenetics in the Disposition of and Response to Tacrolimus in Solid Organ Transplantation. Clinical Pharmacokinetics, 2014, 53, 123-139.	1.6	186
234	Generic tacrolimus in solid organ transplantation. Clinical Transplantation, 2014, 28, 623-632.	0.8	24
235	Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in paediatric liver transplant recipients. British Journal of Clinical Pharmacology, 2014, 77, 1051-1063.	1.1	23
236	Extended-Release Tacrolimus: A Review of Its Use in De Novo Kidney Transplantation. Drugs, 2014, 74, 2053-2064.	4.9	19
237	Improved prediction of tacrolimus concentrations early after kidney transplantation using theoryâ€based pharmacokinetic modelling. British Journal of Clinical Pharmacology, 2014, 78, 509-523.	1.1	67
238	A UK analysis of the cost of switching renal transplant patients from an immediate-release to a prolonged-release formulation of tacrolimus based on differences in trough concentration variability. Journal of Medical Economics, 2014, 17, 520-526.	1.0	7
239	The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients. European Journal of Clinical Pharmacology, 2014, 70, 685-693.	0.8	107
240	Total plasma protein effect on tacrolimus elimination in kidney transplant patients â€“ Population pharmacokinetic approach. European Journal of Pharmaceutical Sciences, 2014, 52, 34-40.	1.9	28

#	Article	IF	Citations
241	Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks. British Journal of Clinical Pharmacology, 2014, 77, 715-728.	1.1	40
242	Association between CYP3A5 Genotypes in Graft Liver and Increase in Tacrolimus Biotransformation from Steroid Treatment in Living-donor Liver Transplant Patients. Drug Metabolism and Pharmacokinetics, 2014, 29, 83-89.	1.1	19
243	Significant Tacrolimus and Dronedarone Interaction in a Kidney Transplant Recipient. Transplantation, 2014, 98, e33-e34.	0.5	6
244	Association of Extrarenal Adverse Effects of Posttransplant Immunosuppression With Sex and ABCB1 Haplotypes. Medicine (United States), 2015, 94, e1315.	0.4	16
245	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clinical Pharmacology and Therapeutics, 2015, 98, 19-24.	2.3	491
246	Delayed trough level measurement with the use of prolonged-release tacrolimus. Transplant International, 2015, 28, 314-318.	0.8	8
247	Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipientsâ€"A Prospective, Randomized Study. Transplantation, 2015, 99, 2158-2166.	0.5	77
248	Estimating the contribution of everolimus to immunosuppressive efficacy when combined with tacrolimus in liver transplantation: A modelâ€based approach. Clinical Pharmacology and Therapeutics, 2015, 97, 411-418.	2.3	5
249	Intracellular sirolimus concentration is reduced by tacrolimus in human pancreatic islets inÂvitro. Transplant International, 2015, 28, 1152-1161.	0.8	7
250	Using Genetic Variation to Predict and Extend Long-term Kidney Transplant Function. Transplantation, 2015, 99, 2038-2048.	0.5	9
251	Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit. British Journal of Clinical Pharmacology, 2015, 80, 548-559.	1.1	48
252	Population pharmacokinetic analysis of tacrolimus in Mexican paediatric renal transplant patients: role of CYP3A5 genotype and formulation. British Journal of Clinical Pharmacology, 2015, 80, 630-641.	1.1	33
253	Data-Driven Percentile Optimization for Multi-Class Queueing Systems with Model Ambiguity: Theory and Application. SSRN Electronic Journal, 0, , .	0.4	1
254	Total Internal Reflection Fluorescence-based Optical Biochip for the Detection of Immunosuppressants in Transplanted Patients. , 2015, , .		2
255	Effects of the CYP3A4*1B Genetic Polymorphism on the Pharmacokinetics of Tacrolimus in Adult Renal Transplant Recipients: A Meta-Analysis. PLoS ONE, 2015, 10, e0127995.	1.1	45
256	Limited sampling strategy for prolonged-release tacrolimus in renal transplant patients by use of the dried blood spot technique. European Journal of Clinical Pharmacology, 2015, 71, 811-816.	0.8	28
257	Race, Calcineurin Inhibitor Exposure, and Renal Function After Solid Organ Transplantation. Transplantation Proceedings, 2015, 47, 2968-2972.	0.3	9
258	The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients. Pharmacogenomics Journal, 2015, 15, 144-152.	0.9	46

#	Article	IF	Citations
259	Potential role of tacrolimus in erythrocytesâ€™ antioxidative capacity in long-term period after renal transplantation. European Journal of Pharmaceutical Sciences, 2015, 70, 132-139.	1.9	1
260	Intra-patient variability in tacrolimus exposure: Causes, consequences for clinical management. Transplantation Reviews, 2015, 29, 78-84.	1.2	161
261	Sublingual tacrolimus as an alternative to oral administration for solid organ transplant recipients. American Journal of Health-System Pharmacy, 2015, 72, 277-284.	0.5	29
262	Pharmacokinetics and pharmacodynamics of tacrolimus in liver transplant recipients: inside the white blood cells. Clinical Biochemistry, 2015, 48, 406-411.	0.8	40
263	Pharmacokinetics and pharmacodynamics of immunosuppressive drugs in elderly kidney transplant recipients. Transplantation Reviews, 2015, 29, 224-230.	1.2	24
264	Capability of Utilizing CYP3A5 Polymorphisms to Predict Therapeutic Dosage of Tacrolimus at Early Stage Post-Renal Transplantation. International Journal of Molecular Sciences, 2015, 16, 1840-1854.	1.8	11
265	Alternative matrices for therapeutic drug monitoring of immunosuppressive agents using LCâ€“MS/MS. Bioanalysis, 2015, 7, 1037-1058.	0.6	38
266	Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients. Clinical Pharmacokinetics, 2015, 54, 993-1025.	1.6	76
267	Induction and Maintenance of Immunosuppression. , 2015, , 1264-1288.		5
268	Associations of HSD11B1 Polymorphisms with Tacrolimus Concentrations in Chinese Renal Transplant Recipients with Prednisone Combined Therapy. Drug Metabolism and Disposition, 2015, 43, 455-458.	1.7	5
269	Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 921-936.	1.5	28
270	Development of a Population PK Model of Tacrolimus for Adaptive Dosage Control in Stable Kidney Transplant Patients. Therapeutic Drug Monitoring, 2015, 37, 246-255.	1.0	29
271	FujicalinÂ®-based solid supersaturable self-emulsifying drug delivery system (S-SEDDS) of tacrolimus for enhanced dissolution rate and oral absorption. Journal of Pharmaceutical Investigation, 2015, 45, 651-658.	2.7	10
272	Effect of CYP3A5 and ABCB1 polymorphisms on the interaction between tacrolimus and itraconazole in patients with connective tissue disease. European Journal of Clinical Pharmacology, 2015, 71, 1091-1097.	0.8	7
273	Conversion of twice-daily to once-daily tacrolimus is safe in stable adult living donor liver transplant recipients. Hepatobiliary and Pancreatic Diseases International, 2015, 14, 374-379.	0.6	16
274	A Simple Novel Technique to Estimate Tacrolimus Dosages During the Early Post Kidney Transplantation Period. Transplantation Proceedings, 2015, 47, 2433-2438.	0.3	4
275	The Tyranny of Generic Immunosuppressants. American Journal of Nephrology, 2016, 44, 204-205.	1.4	1
276	The Oxidative and Inflammatory State in Patients with Acute Renal Graft Dysfunction Treated with Tacrolimus. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-8.	1.9	4

#	Article	IF	Citations
277	Enhanced dissolution and oral absorption of tacrolimus by supersaturable self-emulsifying drug delivery system. International Journal of Nanomedicine, 2016, 11, 1109.	3.3	20
278	Risk factors for and management of ischemic-type biliary lesions following orthotopic liver transplantation: A single center experience. Annals of Hepatology, 2016, 15, 41-46.	0.6	6
279	A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotypeâ€Based With Bodyâ€Weightâ€Based Tacrolimus Dosing After Living Donor Kidney Transplantation. American Journal of Transplantation, 2016, 16, 2085-2096.	2.6	129
280	Effects of tacrolimus on morphology, proliferation and differentiation of mesenchymal stem cells derived from gingiva tissue. Molecular Medicine Reports, 2016, 14, 69-76.	1.1	21
281	A high intrapatient variability in tacrolimus exposure is associated with poor long-term outcome of kidney transplantation. Transplant International, 2016, 29, 1158-1167.	0.8	108
282	Residential Location and Kidney Transplant Outcomes in Indigenous Compared With Nonindigenous Australians. Transplantation, 2016, 100, 2168-2176.	0.5	20
283	External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients. British Journal of Clinical Pharmacology, 2016, 81, 891-907.	1.1	82
284	Limited Sampling Strategy for the Estimation of Tacrolimus Area Under the Concentration-Time Curve in Chinese Adult Liver Transplant Patients. Pharmacology, 2016, 98, 229-241.	0.9	6
286	Immunopharmacological Drugs. , 2016, , 549-572.		2
287	Population Pharmacokinetic Modelling and Bayesian Estimation of Tacrolimus Exposure: Is this Clinically Useful for Dosage Prediction Yet?. Clinical Pharmacokinetics, 2016, 55, 1295-1335.	1.6	69
288	The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients. Clinical Pharmacokinetics, 2016, 55, 1129-1143.	1.6	27
289	Meltdose Tacrolimus Pharmacokinetics. Transplantation Proceedings, 2016, 48, 420-423.	0.3	18
290	Pro: The use of calcineurin inhibitors in the treatment of lupus nephritis. Nephrology Dialysis Transplantation, 2016, 31, 1561-1566.	0.4	19
291	Targeting Kv1.3 channels to reduce white matter pathology after traumatic brain injury. Experimental Neurology, 2016, 283, 188-203.	2.0	18
292	A preliminary study searching for the right dose of tacrolimus in very young (â‰¤4 years) renal transplant patients. Journal of Pharmacy and Pharmacology, 2016, 68, 1366-1372.	1.2	3
293	Tacrolimus-loaded nanostructured lipid carriers for oral delivery â€“ Optimization of production and characterization. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 108, 277-288.	2.0	58
294	Sublingual Tacrolimus in Liver Transplantation: A Valid Option?. Transplantation Proceedings, 2016, 48, 2102-2106.	0.3	2
295	Inter-laboratory Variability of Current Immunoassay Methods for Tacrolimus among Japanese Hospitals. Biological and Pharmaceutical Bulletin, 2016, 39, 1331-1337.	0.6	13

#	Article	IF	Citations
296	A high performance liquid chromatography tandem mass spectrometry for the quantification of tacrolimus in human bile in liver transplant recipients. Journal of Chromatography A, 2016, 1475, 55-63.	1.8	17
297	Development and validation of a sensitive and selective LCâ€“MS/MS method for determination of tacrolimus in oral fluids. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1038, 136-141.	1.2	10
298	Tacrolimus-loaded nanostructured lipid carriers for oral delivery-in vivo bioavailability enhancement. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 109, 149-157.	2.0	38
299	Pharmacogenetic-based strategy using de novo tacrolimus once daily after kidney transplantation: prospective pilot study. Pharmacogenomics, 2016, 17, 1019-1027.	0.6	10
300	Correlation of Hematocrit and Tacrolimus Level in Liver Transplant Recipients. Transplantation Proceedings, 2016, 48, 1176-1178.	0.3	17
301	Advagraf^{Â®}, a once-daily prolonged release tacrolimus formulation, in kidney transplantation: literature review and guidelines from a panel of experts. Transplant International, 2016, 29, 860-869.	0.8	34
302	Design, Characterization, and In Vivo Pharmacokinetics of Tacrolimus Proliposomes. AAPS PharmSciTech, 2016, 17, 1019-1029.	1.5	20
303	Clinical implementation of pharmacogenetics. Drug Metabolism and Personalized Therapy, 2016, 31, 9-16.	0.3	21
304	Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients. European Journal of Clinical Pharmacology, 2016, 72, 163-174.	0.8	43
305	Improved oral absorption of tacrolimus by a solid dispersion with hypromellose and sodium lauryl sulfate. International Journal of Biological Macromolecules, 2016, 83, 282-287.	3.6	27
306	Clinical determinants of calcineurin inhibitor disposition: a mechanistic review. Drug Metabolism Reviews, 2016, 48, 88-112.	1.5	119
307	Therapeutic drug monitoring of immunosuppressants by liquid chromatographyâ€“mass spectrometry. Clinica Chimica Acta, 2016, 454, 1-5.	0.5	55
308	A rapid and sensitive method to determine tacrolimus in rat whole blood using liquidâ€“liquid extraction with mild temperature ultrasonication and LCâ€“MS/MS. Archives of Pharmacal Research, 2016, 39, 73-82.	2.7	9
309	Tacrolimus for the prevention and treatment of rejection of solid organ transplants. Expert Review of Clinical Immunology, 2016, 12, 333-342.	1.3	39
310	Overview of the pharmacology and toxicology of immunosuppressant agents that require therapeutic drug monitoring. , 2016, , 1-27.		2
311	Factors associated with optimized tacrolimus dosing in hematopoietic stem cell transplantation. Journal of Oncology Pharmacy Practice, 2016, 22, 275-283.	0.5	3
312	Genotype-guided tacrolimus dosing in African-American kidney transplant recipients. Pharmacogenomics Journal, 2017, 17, 61-68.	0.9	60
313	Once-daily prolonged-release tacrolimus formulations for kidney transplantation: what the nephrologist needs to know. Journal of Nephrology, 2017, 30, 53-61.	0.9	7

#	Article	IF	Citations
314	First UHPLC-MS/MS method coupled with automated online SPE for quantification both of tacrolimus and everolimus in peripheral blood mononuclear cells and its application on samples from co-treated pediatric patients.. Journal of Mass Spectrometry, 2017, 52, 187-195.	0.7	20
315	Tacrolimus interaction with nafcillin resulting in significant decreases in tacrolimus concentrations: A case report. Transplant Infectious Disease, 2017, 19, e12662.	0.7	6
316	Decreased tacrolimus plasma concentrations during HCV therapy: a drugâ€"drug interaction or is there an alternative explanation?. International Journal of Antimicrobial Agents, 2017, 49, 379-382.	1.1	20
317	The Pharmacogenetics of Tacrolimus in Corticosteroid-Sparse Pediatric and Adult Kidney Transplant Recipients. Drugs in R and D, 2017, 17, 279-286.	1.1	14
318	The CYP3A biomarker 4Î²â€hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation. British Journal of Clinical Pharmacology, 2017, 83, 1457-1465.	1.1	19
319	Prograf produces more benefits for CYP3A5 low expression patients in early stage after kidney transplantation. Biomedicine and Pharmacotherapy, 2017, 88, 738-744.	2.5	4
320	Sublingual tacrolimus administration provides similar drug exposure to perâ€oral route employing lower doses in liver transplantation: a pilot study. Alimentary Pharmacology and Therapeutics, 2017, 45, 1225-1231.	1.9	11
321	Impact of the CYP3A5 genotype on the distributions of dose-adjusted trough concentrations and incidence of rejection in Japanese renal transplant recipients receiving different tacrolimus formulations. Clinical and Experimental Nephrology, 2017, 21, 787-796.	0.7	6
322	Genetic predictors of long-term graft function in kidney and pancreas transplant patients. Briefings in Functional Genomics, 2017, 16, elw039.	1.3	2
323	Tacrolimus population pharmacokinetics according to CYP3A5 genotype and clinical factors in Chinese adult kidney transplant recipients. Journal of Clinical Pharmacy and Therapeutics, 2017, 42, 425-432.	0.7	30
324	CYP3A4 is a crosslink between vitamin D and calcineurin inhibitors in solid organ transplant recipients: implications for bone health. Pharmacogenomics Journal, 2017, 17, 481-487.	0.9	7
325	Fexofenadine, a Putative In Vivo Pâ€glycoprotein Probe, Fails to Predict Clearance of the Substrate Tacrolimus in Renal Recipients. Clinical Pharmacology and Therapeutics, 2017, 102, 989-996.	2.3	10
326	SLC28A3 rs7853758 as a new biomarker of tacrolimus elimination and new-onset hypertension in Chinese liver transplantation patients. Biomarkers in Medicine, 2017, 11, 607-618.	0.6	7
327	4Î²â€Hydroxycholesterol level significantly correlates with steadyâ€state serum concentration of the CYP3A4 substrate quetiapine in psychiatric patients. British Journal of Clinical Pharmacology, 2017, 83, 2398-2405.	1.1	18
328	Application of volumetric absorptive microsampling device for quantification of tacrolimus in human blood as a model drug of high blood cell partition. Journal of Pharmaceutical and Biomedical Analysis, 2017, 143, 168-175.	1.4	46
329	High Tacrolimus Clearance Is a Risk Factor for Acute Rejection in the Early Phase After Renal Transplantation. Transplantation, 2017, 101, e273-e279.	0.5	40
330	Pharmacokinetics of prolongedâ€release tacrolimus versus immediateâ€release tacrolimus in de novo liver transplantation: A randomized phase <scp>III</scp> substudy. Clinical Transplantation, 2017, 31, e12958.	0.8	6
331	Prolonged tacrolimus for pediatric gastrointestinal disorder: Doubleâ€edged sword?. Pediatrics International, 2017, 59, 588-592.	0.2	8

#	Article	IF	Citations
332	Donor CYP3A5 genotype influences tacrolimus disposition on the first day after paediatric liver transplantation. British Journal of Clinical Pharmacology, 2017, 83, 1252-1262.	1.1	19
333	A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach. Clinical Pharmacokinetics, 2017, 56, 963-975.	1.6	69
334	Long-Term Influence of CYP3A5, CYP3A4, ABCB1, and NR1I2 Polymorphisms on Tacrolimus Concentration in Chinese Renal Transplant Recipients. Genetic Testing and Molecular Biomarkers, 2017, 21, 663-673.	0.3	15
335	Variability index of tacrolimus serum levels in pediatric liver transplant recipients younger than 12Âyears: Nonâ€adherence or risk of nonâ€adherence?. Pediatric Transplantation, 2017, 21, e13058.	0.5	12
336	Calcineurin inhibitors in systemic lupus erythematosus. Best Practice and Research in Clinical Rheumatology, 2017, 31, 429-438.	1.4	63
337	Using known drug interactions to manage supratherapeutic calcineurin inhibitor concentrations. Clinical Transplantation, 2017, 31, e13098.	0.8	7
338	Isoglycyrrhizinate Magnesium Enhances Hepatoprotective Effect of FK506 on Ischemia-Reperfusion Injury Through HMGB1 Inhibition in a Rat Model of Liver Transplantation. Transplantation, 2017, 101, 2862-2872.	0.5	9
339	NFATâ€regulated cytokine gene expression during tacrolimus therapy early after renal transplantation. British Journal of Clinical Pharmacology, 2017, 83, 2494-2502.	1.1	25
340	Dried Blood Spot Sampling for Tacrolimus and Mycophenolic Acid in Children: Analytical and Clinical Validation. Therapeutic Drug Monitoring, 2017, 39, 412-421.	1.0	38
341	Effect of Age and Allele Variants of CYP3A5, CYP3A4, and POR Genes on the Pharmacokinetics of Cyclosporin A in Pediatric Renal Transplant Recipients From Serbia. Therapeutic Drug Monitoring, 2017, 39, 589-595.	1.0	15
342	Pharmacokinetics of Mycophenolic Acid and Dose Optimization in Children After Intestinal Transplantation. Therapeutic Drug Monitoring, 2017, 39, 37-42.	1.0	5
343	Prevalence of <scp>CYP</scp>3A5 Genomic Variances and Their Impact on Tacrolimus Dosing Requirements among Kidney Transplant Recipients in Eastern North Carolina. Pharmacotherapy, 2017, 37, 1081-1088.	1.2	14
344	Patient-reported non-adherence and immunosuppressant trough levels are associated with rejection after renal transplantation. BMC Nephrology, 2017, 18, 107.	0.8	48
345	Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation. Transplantation, 2017, 101, 2931-2938.	0.5	57
346	Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients. Transplantation, 2017, 101, 2780-2788.	0.5	13
347	FOXP3 rs3761548 polymorphism is associated with tacrolimus-induced acute nephrotoxicity in renal transplant patients. European Journal of Clinical Pharmacology, 2017, 73, 39-47.	0.8	21
348	Dynamic effects ofCYP3A5polymorphism on dose requirement and trough concentration of tacrolimus in renal transplant recipients. Journal of Clinical Pharmacy and Therapeutics, 2017, 42, 93-97.	0.7	14
349	Overweight Kidney Transplant Recipients Are at Risk of Being Overdosed Following Standard Bodyweight-Based Tacrolimus Starting Dose. Transplantation Direct, 2017, 3, e129.	0.8	30

#	Article	IF	Citations
350	Pharmacoepidemiology of tacrolimus in pediatric liver transplantation. Pediatric Transplantation, 2017, 21, e12982.	0.5	8
351	Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact. Clinical and Translational Science, 2017, 10, 443-454.	1.5	55
352	Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation. Frontiers in Pharmacology, 2017, 8, 358.	1.6	44
353	Tacrolimus Toxicity due to Biliary Obstruction in a Combined Kidney and Liver Transplant Recipient. Case Reports in Transplantation, 2017, 2017, 1-4.	0.1	1
354	Individualizing Transplant Therapy. , 2017, , 255-279.		2
355	Data-Driven Management of Post-Transplant Medications: An APOMDP Approach. SSRN Electronic Journal, 2017, , .	0.4	2
356	New tablet formulation of tacrolimus with smaller interindividual variability may become a better treatment option than the conventional capsule formulation in organ transplant patients. Drug Design, Development and Therapy, 2017, Volume 11, 2861-2869.	2.0	6
357	Pharmacokinetics and Genomics of Immunosuppressive Drugs. , 2017, , 429-443.		1
358	A simple and highly sensitive on-line column extraction liquid chromatography-tandem mass spectrometry method for the determination of protein-unbound tacrolimus in human plasma samples. Journal of Chromatography A, 2018, 1547, 45-52.	1.8	16
359	Impact of the CYP3A5*1 Allele on the Pharmacokinetics of Tacrolimus in Japanese Heart Transplant Patients. European Journal of Drug Metabolism and Pharmacokinetics, 2018, 43, 665-673.	0.6	8
360	Placental disposition of the immunosuppressive drug tacrolimus in renal transplant recipients and in ex vivo perfused placental tissue. European Journal of Pharmaceutical Sciences, 2018, 119, 244-248.	1.9	20
361	CYP3A5*3 and ABCB1 61A>G Significantly Influence Doseâ€adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Postâ€Kidney Transplantation. Basic and Clinical Pharmacology and Toxicology, 2018, 123, 320-326.	1.2	27
362	Phenytoin and Rifampin Do Not Decrease Levels in Acute Tacrolimus Toxicity. Journal of Investigative Medicine High Impact Case Reports, 2018, 6, 232470961876586.	0.3	1
363	Pharmacokinetic models to assist the prescriber in choosing the best tacrolimus dose. Pharmacological Research, 2018, 130, 316-321.	3.1	34
364	Applying genomics in heart transplantation. Transplant International, 2018, 31, 278-290.	0.8	8
365	Tacrolimus Concentration in Saliva of Kidney Transplant Recipients: Factors Influencing the Relationship with Whole Blood Concentrations. Clinical Pharmacokinetics, 2018, 57, 1199-1210.	1.6	12
366	High Intrapatient Variability of Tacrolimus Exposure in the Early Period After Liver Transplantation Is Associated With Poorer Outcomes. Transplantation, 2018, 102, e108-e114.	0.5	52
367	Dose-Response Relationship Between Diltiazem and Tacrolimus and Its Safety in Renal Transplant Recipients. Transplantation Proceedings, 2018, 50, 2515-2520.	0.3	8

#	Article	IF	Citations
368	¹⁸F-FAC PET Selectively Images Liver-Infiltrating CD4 and CD8 T Cells in a Mouse Model of Autoimmune Hepatitis. Journal of Nuclear Medicine, 2018, 59, 1616-1623.	2.8	15
369	Degradation, Intra-Articular Biocompatibility, Drug Release, and Bioactivity of Tacrolimus-Loaded Poly(<scp>d</scp>-<scp>l</scp>-lactide-PEG)-b-poly(<scp>l</scp>-lactide) Multiblock Copolymer-Based Monospheres. ACS Biomaterials Science and Engineering, 2018, 4, 2390-2403.	2.6	10
370	Determination of Tacrolimus Concentration and Protein Expression of P-Glycoprotein in Single Human Renal Core Biopsies. Therapeutic Drug Monitoring, 2018, 40, 292-300.	1.0	10
371	A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation. Clinical Pharmacokinetics, 2018, 57, 475-489.	1.6	48
372	Association of donor small ubiquitinâ€like modifier 4 rs237025 genetic variant with tacrolimus elimination in the early period after liver transplantation. Liver International, 2018, 38, 724-732.	1.9	12
373	Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation. American Journal of Transplantation, 2018, 18, 907-915.	2.6	100
374	Preparation and comparison of tacrolimus-loaded solid dispersion and self-microemulsifying drug delivery system by in vitro/in vivo evaluation. European Journal of Pharmaceutical Sciences, 2018, 114, 74-83.	1.9	22
375	Longitudinal Study of Tacrolimus in Lymphocytes During the First Year After Kidney Transplantation. Therapeutic Drug Monitoring, 2018, 40, 558-566.	1.0	26
376	A Low Fixed Tacrolimus Starting Dose Is Effective and Safe in Chinese Renal Transplantation Recipients. Annals of Transplantation, 2018, 23, 300-309.	0.5	4
377	CYP3A5 genotype-based model to predict tacrolimus dosage in the early postoperative period after living donor liver transplantation . Therapeutics and Clinical Risk Management, 2018, Volume 14, 2119-2126.	0.9	12
378	Tacrolimus Concentrations Measured in Excreted Bile in Liver Transplant Recipients: The STABILE Study. Clinical Therapeutics, 2018, 40, 2088-2098.	1.1	5
379	Therapeutic drug monitoring of tacrolimus and mycophenolic acid in outpatient renal transplant recipients using a volumetric dried blood spot sampling device. British Journal of Clinical Pharmacology, 2018, 84, 2889-2902.	1.1	70
380	Tacrolimus Elimination in Four Patients With a <scp>CYP</scp>3A5*3/*3 <scp>CYP</scp>3A4*22/*22 Genotype Combination. Pharmacotherapy, 2018, 38, e46-e52.	1.2	17
381	Which Kidney Transplant Recipients Can Benefit from the Initial Tacrolimus Dose Reduction?. BioMed Research International, 2018, 2018, 1-9.	0.9	6
382	Integration of Genomic Data with NMR Analysis Enables Assignment of the Full Stereostructure of Neaumycin B, a Potent Inhibitor of Glioblastoma from a Marine-Derived Micromonospora. Journal of the American Chemical Society, 2018, 140, 10775-10784.	6.6	51
383	Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of Tacrolimus in Kidney Transplantation. Current Drug Metabolism, 2018, 19, 513-522.	0.7	103
384	Evaluating tacrolimus pharmacokinetic models in adult renal transplant recipients with different CYP3A5 genotypes. European Journal of Clinical Pharmacology, 2018, 74, 1437-1447.	0.8	13
385	Analysis of FK506â€mediated functional recovery and neuroprotection in a rat model of spinal cord injury indicates that EGF is modulated in astrocytes. Experimental and Therapeutic Medicine, 2018, 16, 501-510.	0.8	7

#	Article	IF	Citations
386	Prediction of Tacrolimus Exposure by CYP3A5 Genotype and Exposure of Co-Administered Everolimus in Japanese Renal Transplant Recipients. International Journal of Molecular Sciences, 2018, 19, 882.	1.8	9
387	Increase in tacrolimus exposure after steroid tapering is influenced by CYP3A5 and pregnane X receptor genetic polymorphisms in renal transplant recipients. Nephrology Dialysis Transplantation, 2018, 33, 1668-1675.	0.4	9
388	Update on cellular encapsulation. Xenotransplantation, 2018, 25, e12399.	1.6	16
389	No Significant Influence of Reduced Initial Tacrolimus Dose on Risk of Underdosing and Early Graft Function in Older and Overweight Kidney Transplant Recipients. Transplantation Proceedings, 2018, 50, 1755-1759.	0.3	3
390	Onceâ€daily, prolongedâ€release tacrolimus vs twiceâ€daily, immediateâ€release tacrolimus in de novo livingâ€donor liver transplantation: A Phase 4, randomized, openâ€label, comparative, singleâ€center study. Clinical Transplantation, 2018, 32, e13376.	0.8	6
391	CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment. Pharmacogenomics and Personalized Medicine, 2018, Volume 11, 23-33.	0.4	36
392	Impact of POR and CYP3A5 Polymorphisms on Trough Concentration to Dose Ratio of Tacrolimus in the Early Post-operative Period Following Kidney Transplantation. Therapeutic Drug Monitoring, 2018, 40, 549-557.	1.0	16
393	The Pharmacogenetics of Immune-Modulating Therapy. Advances in Pharmacology, 2018, 83, 275-296.	1.2	4
394	Drug-metabolizing enzymes CYP3A as a link between tacrolimus and vitamin D in renal transplant recipients: is it relevant in clinical practice?. Pediatric Nephrology, 2019, 34, 1201-1210.	0.9	8
395	Weightâ€based tacrolimus trough concentrations post liver transplant. Internal Medicine Journal, 2019, 49, 79-83.	0.5	3
396	Psychopharmacology in transplantation medicine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 88, 74-85.	2.5	8
397	Model based development of tacrolimus dosing algorithm considering CYP3A5 genotypes and mycophenolate mofetil drug interaction in stable kidney transplant recipients. Scientific Reports, 2019, 9, 11740.	1.6	5
399	A new HPLC-MS/MS method for simultaneous determination of Cyclosporine A, Tacrolimus, Sirolimus and Everolimus for routine therapeutic drug monitoring. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1128, 121772.	1.2	34
400	Severe Anti-N-Methyl-D-Aspartate Receptor Encephalitis Under Immunosuppression After Liver Transplantation. Frontiers in Neurology, 2019, 10, 987.	1.1	12
401	Toward a robust tool for pharmacokineticâ€based personalization of treatment with tacrolimus in solid organ transplantation: A modelâ€based metaâ€analysis approach. British Journal of Clinical Pharmacology, 2019, 85, 2793-2823.	1.1	17
402	Limited sampling strategy to predict the area under the curve of tacrolimus in Mexican renal transplant pediatric patients receiving Prograf^{Â®} or nonâ€innovator formulations. Pediatric Transplantation, 2019, 23, e13595.	0.5	5
403	Pharmacokinetics of tacrolimus granules in pediatric de novo liver, kidney, and heart transplantation: The OPTION study. Pediatric Transplantation, 2019, 23, e13328.	0.5	2
404	Pharmacokinetics of Onceâ€Daily ExtendedâÉRelease Tacrolimus Tablets Versus Twiceâ€Daily Capsules in De Novo Liver Transplant. Clinical Pharmacology in Drug Development, 2019, 8, 995-1008.	0.8	10

#	Article	IF	Citations
405	Prediction of tacrolimus dosage in the early period after heart transplantation: a population pharmacokinetic approach. Pharmacogenomics, 2019, 20, 21-35.	0.6	21
406	A randomized, openâ€label pharmacokinetic trial of tacrolimus extendedâ€release dosing in obese de novo kidney transplant recipients. Clinical Transplantation, 2019, 33, e13640.	0.8	4
407	Coadministration of Erythromycin to Increase Tacrolimus Concentrations in Liver Transplant Recipients. Transplantation Proceedings, 2019, 51, 1439-1441.	0.3	3
408	A Minimal Physiologicallyâ€Based Pharmacokinetic Model for Tacrolimus in Livingâ€Donor Liver Transplantation: Perspectives Related to Liver Regeneration and the cytochrome P450 3A5 (CYP3A5) Genotype. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 587-595.	1.3	7
409	Effect of Serum Parathyroid Hormone on Tacrolimus Therapy in Kidney Transplant Patients: A Possible Biomarker for a Tacrolimus Dosage Schedule. Biological and Pharmaceutical Bulletin, 2019, 42, 786-791.	0.6	6
410	Probable sirolimus-induced rupture of arterial anastomosis after liver transplantation in a patient intolerant of tacrolimus. Hepatobiliary and Pancreatic Diseases International, 2019, 18, 398-400.	0.6	3
411	Identification of Factors Affecting Tacrolimus Trough Levels in Latin American Pediatric Liver Transplant Patients. Liver Transplantation, 2019, 25, 1397-1407.	1.3	3
412	Highâ€sensitivity simultaneous quantification of tacrolimus and 13â€•O â€demethyl tacrolimus in human whole blood using ultraâ€performance liquid chromatography coupled to tandem mass spectrometry. Biomedical Chromatography, 2019, 33, e4584.	0.8	8
413	Therapeutic concentration achievement and allograft survival comparing usage of conventional tacrolimus doses and CYP3A5 genotypeâ€guided doses in renal transplantation patients. British Journal of Clinical Pharmacology, 2019, 85, 1964-1973.	1.1	18
414	The Effects of CYP3A5 Genetic Polymorphisms on Serum Tacrolimus Dose-Adjusted Concentrations and Long-Term Prognosis in Chinese Heart Transplantation Recipients. European Journal of Drug Metabolism and Pharmacokinetics, 2019, 44, 771-776.	0.6	7
415	Improved in vivo performance and immunomodulatory effect of novel Omega-3 fatty acid based Tacrolimus nanostructured lipid carrier. Journal of Drug Delivery Science and Technology, 2019, 52, 138-149.	1.4	14
416	Wuzhi capsule and haemoglobin influence tacrolimus elimination in paediatric kidney transplantation patients in a population pharmacokinetics analysis: A retrospective study. Journal of Clinical Pharmacy and Therapeutics, 2019, 44, 611-617.	0.7	26
417	Evaluation of Clinical and Safety Outcomes Following Uncontrolled Tacrolimus Conversion in Adult Transplant Recipients. Pharmacotherapy, 2019, 39, 564-575.	1.2	2
418	Treatment of prolonged tacrolimus toxicity using phenytoin in a haemodialysis patient. Journal of Clinical Pharmacy and Therapeutics, 2019, 44, 640-643.	0.7	6
419	Population pharmacokinetics of immediateâ€•and prolongedâ€release tacrolimus formulations in liver, kidney and heart transplant recipients. British Journal of Clinical Pharmacology, 2019, 85, 1692-1703.	1.1	23
420	Dosage Optimization Based on Population Pharmacokinetic Analysis of Tacrolimus in Chinese Patients with Nephrotic Syndrome. Pharmaceutical Research, 2019, 36, 45.	1.7	18
421	Tacrolimus Variability: A Cause of Donor-Specific Anti-HLA Antibody Formation in Children. European Journal of Drug Metabolism and Pharmacokinetics, 2019, 44, 539-548.	0.6	12
423	4Î²â€Hydroxycholesterol as an Endogenous Biomarker for CYP3A Activity: Literature Review and Critical Evaluation. Journal of Clinical Pharmacology, 2019, 59, 611-624.	1.0	24

#	Article	IF	Citations
424	Tacrolimus Therapeutic Drug Monitoring in Stable Kidney Transplantation and Individuation of CYP3A5 Genotype. Transplantation Proceedings, 2019, 51, 2917-2920.	0.3	7
425	Tacrolimus Can Be Reliably Measured With Volumetric Absorptive Capillary Microsampling Throughout the Dose Interval in Renal Transplant Recipients. Therapeutic Drug Monitoring, 2019, 41, 607-614.	1.0	43
426	High Intrapatient Variability in Tacrolimus Exposure Is Not Associated With Immune-mediated Graft Injury After Liver Transplantation. Transplantation, 2019, 103, 2329-2337.	0.5	15
427	Estimation of Blood Sirolimus Concentration Based on Tacrolimus Concentration/Dose Normalized by Body Weight Ratio in Lung Transplant Patients. Therapeutic Drug Monitoring, 2019, 41, 615-619.	1.0	4
428	Clinically useful limited sampling strategy to estimate area under the concentration-time curve of once-daily tacrolimus in adult Japanese kidney transplant recipients. PLoS ONE, 2019, 14, e0225878.	1.1	4
429	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Therapeutic Drug Monitoring, 2019, 41, 261-307.	1.0	374
430	Association of Intrapatient Variability of Tacrolimus Concentration With Early Deterioration of Chronic Histologic Lesions in Kidney Transplantation. Transplantation Direct, 2019, 5, e455.	0.8	17
431	<scp>TLR</scp>9 rs352139 Genetic Variant Promotes Tacrolimus Elimination in Chinese Liver Transplant Patients During the Early Posttransplantation Period. Pharmacotherapy, 2019, 39, 67-76.	1.2	5
432	A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients. British Journal of Clinical Pharmacology, 2019, 85, 601-615.	1.1	56
433	Commensal Gut Bacteria Convert the Immunosuppressant Tacrolimus to Less Potent Metabolites. Drug Metabolism and Disposition, 2019, 47, 194-202.	1.7	91
434	The impact of tacrolimus exposure on extrarenal adverse effects in adult renal transplant recipients. British Journal of Clinical Pharmacology, 2019, 85, 516-529.	1.1	20
435	Pharmacogenetics of Membrane Transporters of Tacrolimus in Solid Organ Transplantation. Clinical Pharmacokinetics, 2019, 58, 593-613.	1.6	37
436	Tacrolimus overexposure in kidney transplant recipients during the first postâ€operative week: caution is required in older patients. Fundamental and Clinical Pharmacology, 2019, 33, 347-354.	1.0	2
437	Identification of genetic variants associated with tacrolimus metabolism in kidney transplant recipients by extreme phenotype sampling and next generation sequencing. Pharmacogenomics Journal, 2019, 19, 375-389.	0.9	11
438	The potential impact of hematocrit correction on evaluation of tacrolimus target exposure in pediatric kidney transplant patients. Pediatric Nephrology, 2019, 34, 507-515.	0.9	13
439	Highly sensitive and rapid determination of tacrolimus in peripheral blood mononuclear cells by liquid chromatographyâ€“tandem mass spectrometry. Biomedical Chromatography, 2019, 33, e4416.	0.8	23
440	Population Pharmacokinetics of Tacrolimus in Transplant Recipients: What Did We Learn About Sources of Interindividual Variabilities?. Journal of Clinical Pharmacology, 2019, 59, 309-325.	1.0	50
441	Assessment of tacrolimus intrapatient variability in stable adherent transplant recipients: Establishing baseline values. American Journal of Transplantation, 2019, 19, 1410-1420.	2.6	79

#	Article	IF	Citations
442	Isotopeâ€“labeled versus analog internal standard in LCâ€“MS/MS method for tacrolimus determination in human whole blood samples â€“ A compensation of matrix effects. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1104, 220-227.	1.2	11
443	High tacrolimus clearance - a risk factor for development of interstitial fibrosis and tubular atrophy in the transplanted kidney: a retrospective single-center cohort study. Transplant International, 2019, 32, 257-269.	0.8	16
444	Tacrolimus diffusion across the peripheral mononuclear blood cell membrane: impact of drug transporters. Fundamental and Clinical Pharmacology, 2019, 33, 113-121.	1.0	12
445	Clinical aspects of tacrolimus use in paediatric renal transplant recipients. Pediatric Nephrology, 2019, 34, 31-43.	0.9	20
446	Model extrapolation to a real-world dataset: evaluation of tacrolimus population pharmacokinetics and drug interaction in pediatric liver transplantation patients. Xenobiotica, 2020, 50, 371-379.	0.5	22
447	Population pharmacokinetics and dosing regimen optimization of tacrolimus in Chinese pediatric hematopoietic stem cell transplantation patients. Xenobiotica, 2020, 50, 188-195.	0.5	19
448	Impact of body composition on pharmacokinetics of tacrolimus in liver transplantation recipients. Xenobiotica, 2020, 50, 196-201.	0.5	3
449	Effects of Maribavir on Pâ€Glycoprotein and CYP2D6 in Healthy Volunteers. Journal of Clinical Pharmacology, 2020, 60, 96-106.	1.0	6
450	Pharmacogenomics analysis in Chinese pediatric liver transplantation patients with renal toxicity induced by tacrolimus. Xenobiotica, 2020, 50, 488-493.	0.5	7
451	Tacrolimus: 20 years of use in adult kidney transplantation. What we should know about its nephrotoxicity. Artificial Organs, 2020, 44, 140-152.	1.0	84
452	The association between trough blood concentration and systemic exposure of tacrolimus: Comparison between once-daily (AdvagrafÂ®) and twice-daily (PrografÂ®) formulation in de novo kidney transplant recipients. Drug Metabolism and Pharmacokinetics, 2020, 35, 139-144.	1.1	1
453	A Population Pharmacokinetic Model Does Not Predict the Optimal Starting Dose of Tacrolimus in Pediatric Renal Transplant Recipients in a Prospective Study: Lessons Learned and Model Improvement. Clinical Pharmacokinetics, 2020, 59, 591-603.	1.6	14
454	Early Tacrolimus Concentrations After Lung Transplant Are Predicted by Combined Clinical and Genetic Factors and Associated With Acute Kidney Injury. Clinical Pharmacology and Therapeutics, 2020, 107, 462-470.	2.3	30
455	Impact of Donor and Recipient CYP3A5*3 Genotype on Tacrolimus Population Pharmacokinetics in Chinese Adult Liver Transplant Recipients. Annals of Pharmacotherapy, 2020, 54, 652-661.	0.9	10
456	Tacrolimus Intrapatient Variability, Time in Therapeutic Range, and Risk of De Novo Donorâ€Specific Antibodies. Transplantation, 2020, 104, 881-887.	0.5	39
457	Tacrolimus Area Under the Concentration Versus Time Curve Monitoring, Using Home-Based Volumetric Absorptive Capillary Microsampling. Therapeutic Drug Monitoring, 2020, 42, 407-414.	1.0	20
458	Dosing Requirements of Extended-Release Tacrolimus (Astagraf XL) in African American Kidney Transplant Recipients Converted from Immediate-Release Tacrolimus (AAAKTRS). Therapeutic Drug Monitoring, 2020, 42, 415-420.	1.0	0
459	Assessment of Clinically Relevant Drug Interactions by Online Programs in Renal Transplant Recipients. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 1291-1296.	0.5	5

#	Article	IF	Citations
460	Frequency of CYP3A5 Genetic Polymorphisms and Tacrolimus Pharmacokinetics in Pediatric Liver Transplantation. Pharmaceutics, 2020, 12, 898.	2.0	11
461	Preâ€emptive immunosuppression using tacrolimus monotherapy does not reduce the rate of early acute rejection in renal transplantation from live donors: a comparative cohort study. Transplant International, 2020, 33, 1754-1761.	0.8	1
462	Evaluation of the impact of Tacrolimus-based immunosuppression on Heidelberg liver transplant cohort (HDTACRO). Medicine (United States), 2020, 99, e22180.	0.4	0
463	Dosing algorithm for Tacrolimus in Tunisian Kidney transplant patients: Effect of CYP 3A4*1B and CYP3A4*22 polymorphisms. Toxicology and Applied Pharmacology, 2020, 407, 115245.	1.3	6
464	Tacrolimus Starting Dose Prediction Based on Genetic Polymorphisms and Clinical Factors in Chinese Renal Transplant Recipients. Genetic Testing and Molecular Biomarkers, 2020, 24, 665-673.	0.3	9
465	Impacts of High Intra- and Inter-Individual Variability in Tacrolimus Pharmacokinetics and Fast Tacrolimus Metabolism on Outcomes of Solid Organ Transplant Recipients. Journal of Clinical Medicine, 2020, 9, 2193.	1.0	15
466	Use of phenytoin for treatment of tacrolimus toxicity with superimposed sepsis. BMJ Case Reports, 2020, 13, e234839.	0.2	5
467	Traditional Drugs: Mechanisms of Immunosuppressor and Corticosteroid Therapies for Inflammatory Bowel Diseases. , 2020, , .		1
468	Maintenance Immunosuppression in Solid Organ Transplantation: Integrating Novel Pharmacodynamic Biomarkers to Inform Calcineurin Inhibitor Dose Selection. Clinical Pharmacokinetics, 2020, 59, 1317-1334.	1.6	1
469	The Effect of Topical Tacrolimus on Pedicled Flap Survival. Annals of Plastic Surgery, 2020, 85, S118-S121.	0.5	3
470	Appropriateness of tacrolimus therapeutic drug monitoring timing in the emergency department. American Journal of Emergency Medicine, 2021, 45, 233-236.	0.7	0
471	Single-Molecule Orthogonal Double-Click Chemistryâ€"Inorganic to Organic Nanostructure Transition. ACS Applied Materials & Interfaces, 2020, 12, 27737-27744.	4.0	4
473	A comprehensive review of the impact of tacrolimus intrapatient variability on clinical outcomes in kidney transplantation. American Journal of Transplantation, 2020, 20, 1969-1983.	2.6	51
474	Effects of CYP3A5, ABCB1 and POR*28 polymorphisms on pharmacokinetics of tacrolimus in the early period after renal transplantation. Xenobiotica, 2020, 50, 1501-1509.	0.5	10
475	Efficacy and safety of three times daily dosing of tacrolimus in pediatric kidney transplantation patients: A singleâ€center comparative study. Pediatric Transplantation, 2020, 24, e13733.	0.5	3
476	Exploratory Analysis of the Impact of an mHealth Medication Adherence Intervention on Tacrolimus Trough Concentration Variability: Post Hoc Results of a Randomized Controlled Trial. Annals of Pharmacotherapy, 2020, 54, 1185-1193.	0.9	32
477	Influence of CYP3A5 Genetic Polymorphism on Long-Term Renal Function in Chinese Kidney Transplant Recipients Using Limited Sampling Strategy and Abbreviated Area Under the Curve for Tacrolimus Monitoring. Progress in Transplantation, 2020, 30, 249-253.	0.4	1
478	Relationship Between Change Rate of Tacrolimus Clearance During Continuous Intravenous Infusion and Recipient Recovery at an Early Stage After Living Donor Liver Transplantation. European Journal of Drug Metabolism and Pharmacokinetics, 2020, 45, 619-626.	0.6	1

#	Article	IF	Citations
479	Gut microbiota in reductive drug metabolism. Progress in Molecular Biology and Translational Science, 2020, 171, 61-93.	0.9	24
480	Population Pharmacokinetic Analysis of Tacrolimus in Adult Chinese Patients with Myasthenia Gravis: A Prospective Study. European Journal of Drug Metabolism and Pharmacokinetics, 2020, 45, 453-466.	0.6	7
481	Influence of POR*28 Polymorphisms on CYP3A5*3-Associated Variations in Tacrolimus Blood Levels at an Early Stage after Liver Transplantation. International Journal of Molecular Sciences, 2020, 21, 2287.	1.8	10
482	Pharmacogeneticâ€"Whole blood and intracellular pharmacokineticâ€"Pharmacodynamic (PG-PK2-PD) relationship of tacrolimus in liver transplant recipients. PLoS ONE, 2020, 15, e0230195.	1.1	24
483	Failure of Achieving Tacrolimus Target Blood Concentration Might Be Avoided by a Wide Genotyping of Transplanted Patients: Evidence from a Retrospective Study. Journal of Personalized Medicine, 2020, 10, 47.	1.1	2
484	The pharmacogenetics of tacrolimus and its implications for personalized therapy in kidney transplant recipients. Expert Review of Precision Medicine and Drug Development, 2020, 5, 313-316.	0.4	4
485	Population pharmacokinetics and dosing regimen optimization of tacrolimus in Chinese lung transplant recipients. European Journal of Pharmaceutical Sciences, 2020, 152, 105448.	1.9	20
486	Influence of Germline Genetics on Tacrolimus Pharmacokinetics and Pharmacodynamics in Allogeneic Hematopoietic Stem Cell Transplant Patients. International Journal of Molecular Sciences, 2020, 21, 858.	1.8	16
487	Immunosuppression with generic tacrolimus in liver and kidney transplantationâ€"systematic review and metaâ€analysis on biopsyâ€proven acute rejection and bioequivalence. Transplant International, 2020, 33, 356-372.	0.8	7
488	Systematic external evaluation of published population pharmacokinetic models for tacrolimus in adult liver transplant recipients. European Journal of Pharmaceutical Sciences, 2020, 145, 105237.	1.9	24
489	Precision Dosing Priority Criteria: Drug, Disease, and Patient Population Variables. Frontiers in Pharmacology, 2020, 11, 420.	1.6	45
490	Effect of CYP3A4*22 and CYP3A4*1B but not CYP3A5*3 polymorphisms on tacrolimus pharmacokinetic model in Tunisian kidney transplant. Toxicology and Applied Pharmacology, 2020, 396, 115000.	1.3	7
491	The effects of targeted immune-regulatory strategies on tumor-specific T-cell responses in vitro. Cancer Immunology, Immunotherapy, 2021, 70, 1771-1776.	2.0	8
492	A simple and fast liquid chromatography tandem mass spectrometry method to determine cyclosporine A concentrations in endomyocardial biopsies. Journal of Pharmaceutical and Biomedical Analysis, 2021, 193, 113664.	1.4	3
493	Inhibition effect of epigallocatechin-3-gallate on the pharmacokinetics of calcineurin inhibitors, tacrolimus, and cyclosporine A, in rats. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 121-134.	1.5	7
494	Population pharmacokinetics of tacrolimus in umbilical cord blood transplant patients focusing on the variation in red blood cell counts. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 190-197.	0.7	4
495	Diltiazem on tacrolimus exposure and dose sparing in Chinese pediatric primary nephrotic syndrome: impact of CYP3A4, CYP3A5, ABCB1, and SLCO1B3 polymorphisms. European Journal of Clinical Pharmacology, 2021, 77, 71-77.	0.8	7
496	Evaluation of the performance of a prior tacrolimus population pharmacokinetic kidney transplant model among adult allogeneic hematopoietic stem cell transplant patients. Clinical and Translational Science, 2021, 14, 908-918.	1.5	4

#	Article	IF	Citations
497	FK506-loaded PLGA nanoparticles improve long-term survival of a vascularized composite allograft in a murine model. Annals of Translational Medicine, 2021, 9, 1515-1515.	0.7	1
499	Fastâ€Track Liver Transplantation: Sixâ€year Prospective Cohort Study with an Enhanced Recovery After Surgery (ERAS) Protocol. World Journal of Surgery, 2021, 45, 1262-1271.	0.8	29
500	Precision Dosing for Tacrolimus Using Genotypes and Clinical Factors in Kidney Transplant Recipients of European Ancestry. Journal of Clinical Pharmacology, 2021, 61, 1035-1044.	1.0	3
501	Avoiding Tacrolimus Underexposure and Overexposure with a Dosing Algorithm for Renal Transplant Recipients: A Single Arm Prospective Intervention Trial. Clinical Pharmacology and Therapeutics, 2021, 110, 169-178.	2.3	24
503	BK Polyomavirus Nephropathy in Kidney Transplantation: Balancing Rejection and Infection. Viruses, 2021, 13, 487.	1.5	32
504	Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal transplant recipients. British Journal of Clinical Pharmacology, 2021, 87, 3901-3909.	1.1	13
505	Functional CYP3A variants affecting tacrolimus trough blood concentrations in Chinese renal transplant recipients. Pharmacogenomics Journal, 2021, 21, 376-389.	0.9	5
506	Influence of the Circadian Timing System on Tacrolimus Pharmacokinetics and Pharmacodynamics After Kidney Transplantation. Frontiers in Pharmacology, 2021, 12, 636048.	1.6	14
507	Population pharmacokinetic analysis and dosing guidelines for tacrolimus coâ€administration with Wuzhi capsule in Chinese renal transplant recipients. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 1117-1128.	0.7	16
508	Tacrolimus Exposure in Obese Patients: and A Caseâ€“Control Study in Kidney Transplantation. Therapeutic Drug Monitoring, 2021, 43, 229-237.	1.0	6
509	Evaluation of Bayesian Forecasting Methods for Prediction of Tacrolimus Exposure Using Samples Taken on Two Occasions in Adult Kidney Transplant Recipients. Therapeutic Drug Monitoring, 2021, 43, 238-246.	1.0	5
510	Evaluating risk factors for acute graft versus host disease in pediatric hematopoietic stem cell transplant patients receiving tacrolimus. Clinical and Translational Science, 2021, 14, 1303-1313.	1.5	3
511	Population pharmacokinetics and genetics of oral meltdose tacrolimus (Envarsus) in stable adult liver transplant recipients. British Journal of Clinical Pharmacology, 2021, 87, 4262-4272.	1.1	8
512	Association of CYP3A5 polymorphisms and parathyroid hormone with blood level of tacrolimus in patients with endâ€stage renal disease. Clinical and Translational Science, 2021, 14, 2034-2042.	1.5	6
513	Efficacy of Tacrolimus in Uveitis, and the Usefulness of Serum Tacrolimus Levels in Predicting Disease Control. Results from a Single Large Center. Ocular Immunology and Inflammation, 2022, 30, 1654-1658.	1.0	5
514	Treatment optimization of maintenance immunosuppressive agents in pediatric renal transplant recipients. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 747-765.	1.5	1
515	CYP3A5*3 polymorphism and age affect tacrolimus blood trough concentration in myasthenia gravis patients. Journal of Neuroimmunology, 2021, 355, 577571.	1.1	1
516	Role of Tacrolimus C/D Ratio in the First Year After Pediatric Liver Transplantation. Frontiers in Pediatrics, 2021, 9, 659608.	0.9	5

#	Article	IF	Citations
517	Tacrolimus Therapy in Adult Heart Transplant Recipients. Therapeutic Drug Monitoring, 2021, Publish Ahead of Print, 736-746.	1.0	3
518	Metabolism and transporter based drugâ€“drug interaction of tacrolimus with nine co-medicated injections. Medicine in Drug Discovery, 2021, 10, 100091.	2.3	0
519	When Paranoia Comes with the Treatment: Psychosis Associated with Tacrolimus Use. Case Reports in Nephrology and Dialysis, 2021, 11, 241-246.	0.3	4
520	Effects and safety evaluation of Wuzhi Capsules combined with tacrolimus for the treatment of kidney transplantation recipients. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 1636-1649.	0.7	12
521	Can We Predict Individual Concentrations of Tacrolimus After Liver Transplantation? Application and Tweaking of a Published Population Pharmacokinetic Model in Clinical Practice. Therapeutic Drug Monitoring, 2021, 43, 490-498.	1.0	5
522	Evaluation of published population pharmacokinetic models to inform tacrolimus dosing in adult heart transplant recipients. British Journal of Clinical Pharmacology, 2021, , .	1.1	3
523	Comparing the pharmacokinetics of extended-release tacrolimus (LCP-TAC) to immediate-release formulations in kidney transplant patients. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 1175-1186.	1.5	3
524	Therapeutic Drug Monitoring Strategies for Envarsus in De Novo Kidney Transplant Patients Using Population Modelling and Simulations. Advances in Therapy, 2021, 38, 5317-5332.	1.3	4
525	High Intrapatient Variability in Tacrolimus Exposure Calculated Over a Long Period Is Associated With De Novo Donor-Specific Antibody Development and/or Late Rejection in Thai Kidney Transplant Patients Receiving Concomitant CYP3A4/5 Inhibitors. Therapeutic Drug Monitoring, 2021, 43, 624-629.	1.0	4
526	Extrapolation of physiologically based pharmacokinetic model for tacrolimus from renal to liver transplant patients. Drug Metabolism and Pharmacokinetics, 2022, 42, 100423.	1.1	2
527	Post-transplant Medication Challenges. , 2021, , 305-356.		0
528	Immunosuppressive therapy in SLE. , 2021, , 623-659.		0
529	Immunosuppressive Drugs. , 2008, , 165-199.		4
530	CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Pharmacogenetics and Genomics, 2008, 18, 339-348.	0.7	110
531	Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers. Pharmacogenetics and Genomics, 2011, 21, 713-720.	0.7	64
532	Calcineurin-independent inhibition of KV1.3 by FK-506 (tacrolimus): a novel pharmacological property. American Journal of Physiology - Cell Physiology, 2007, 292, C1714-C1722.	2.1	13
533	Effects of Wuzhi Capsules on Blood Concentration of Tacrolimus in Renal Transplant Recipients. Annals of Transplantation, 2019, 24, 594-604.	0.5	16
534	Effect of Concentration/Dose Ratio in De Novo Kidney Transplant Recipients Receiving LCP-Tacrolimus or Immediate-Release Tacrolimus: Post Hoc Analysis of a Phase 3 Clinical Trial. Annals of Transplantation, 2020, 25, e923278.	0.5	6

#	Article	IF	Citations
535	Population Pharmacokinetic Analysis of Tacrolimus in Adult Mexican Patients with Renal Transplant. Biomedical and Pharmacology Journal, 2015, 8, 47-56.	0.2	2
536	ABCB1 1199G>A Genetic Polymorphism (Rs2229109) Influences the Intracellular Accumulation of Tacrolimus in HEK293 and K562 Recombinant Cell Lines. PLoS ONE, 2014, 9, e91555.	1.1	38
537	Cost Evaluation of Dried Blood Spot Home Sampling as Compared to Conventional Sampling for Therapeutic Drug Monitoring in Children. PLoS ONE, 2016, 11, e0167433.	1.1	66
539	A new donorsâ€™ CYP3A5 and recipientsâ€™ CYP3A4 cluster predicting tacrolimus disposition, and new-onset hypertension in Chinese liver transplant patients. Oncotarget, 2017, 8, 70250-70261.	0.8	3
540	Non-linear Relationship between Tacrolimus Blood Concentration and Acute Rejection After Kidney Transplantation: A Systematic Review and Dose-Response Meta-Analysis of Cohort Studies. Current Pharmaceutical Design, 2019, 25, 2394-2403.	0.9	4
541	Association of Genetic Variants in CYP3A4, CYP3A5, CYP2C8, and CYP2C19 with Tacrolimus Pharmacokinetics in Renal Transplant Recipients. Current Drug Metabolism, 2019, 20, 609-618.	0.7	8
542	â€œSmartphone Medication Adherence Saves Kidneysâ€•for Kidney Transplantation Recipients: Protocol for a Randomized Controlled Trial. JMIR Research Protocols, 2019, 8, e13351.	0.5	8
543	Prognostic value of endogenous and exogenous metabolites in liver transplantation. Biomarkers in Medicine, 2020, 14, 1165-1181.	0.6	2
544	Effects of CYP3A5 polymorphism and the tacrolimus 12â€‰h concentration on tacrolimus-induced acute renal dysfunction in patients with lupus nephritis. Xenobiotica, 2015, 45, 1147-53.	0.5	1
545	High tacrolimus intra-patient variability is associated with graft rejection, and de novo donor-specific antibodies occurrence after liver transplantation. World Journal of Gastroenterology, 2018, 24, 1795-1802.	1.4	63
546	Importance of genetic polymorphisms in liver transplantation outcomes. World Journal of Gastroenterology, 2020, 26, 1273-1285.	1.4	12
547	Tacrolimus increases the expression level of the chemokine receptor CXCR2 to promote renal fibrosis progression. International Journal of Molecular Medicine, 2019, 44, 2181-2188.	1.8	10
548	The impact of CYP3A5 and MDR1 polymorphisms on tacrolimus dosage requirements and trough concentrations in pediatric renal transplant recipients. Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2013, 24, 1125.	0.4	7
549	Pharmacokinetic Changes Secondary to Roux en Y Gastric Bypass. Advances in Pharmacoepidemiology & Drug Safety, 2012, 01, .	0.1	2
550	Effects of Cholestasis on Whole Blood Concentration of Tacrolimus, an Immunosuppressant, in Living-Related Liver Transplant Recipients. International Journal of Clinical Medicine, 2013, 04, 432-439.	0.1	2
551	Increased Tacrolimus Levels After Administration of Ciprofloxacin to a Patient with Renal Transplant. Turkish Nephrology, Dialysis and Transplantation Journal, 2016, 25, .	0.0	1
552	Intrapatient Variability in Tacrolimus Exposure Does Not Predict The Development of Cardiac Allograft Vasculopathy After Heart Transplant. Experimental and Clinical Transplantation, 2018, 16, 326-332.	0.2	5
553	Tacrolimus: review of pharmacokinetics, pharmacodynamics, and pharmacogenetics to facilitate practitioners' understanding and offer strategies for educating patients and promoting adherence. Progress in Transplantation, 2009, 19, 277-284.	0.4	41

#	Article	IF	Citations
554	Effects of bile duct stricture on the pharmacokinetics of the immunosuppressant tacrolimus in rats. Interactive Medicinal Chemistry, 2013, 1, 1.	0.0	3
555	Tacrolimus Dose-Conversion Ratios Based on Switching of Formulations for Patients with Solid Organ Transplants. Canadian Journal of Hospital Pharmacy, 2021, 74, 317-326.	0.1	0
556	Outcomes of De Novo Use of Generic Tacrolimus (AdoportÂ®) in Living-Related Kidney Transplantation: A Single-Center, Real-Life Experience of 5 Years. , 2021, 30, 255-261.		0
557	Monitoring Intra-cellular Tacrolimus Concentrations in Solid Organ Transplantation: Use of Peripheral Blood Mononuclear Cells and Graft Biopsy Tissue. Frontiers in Pharmacology, 2021, 12, 733285.	1.6	12
558	3. Tacrolimus. Japanese Journal of Clinical Pharmacology and Therapeutics, 2005, 36, 58-62.	0.1	0
559	Drug interactions medicine. , 2010, , 281-308.		0
560	The impact of a change in tacrolimus monitoring immunoassay techniques on clinical decision making. Progress in Transplantation, 2010, 20, 350-356.	0.4	0
561	Study on the Pharmacokinetics of Tacrolimus in Depression Model Rats. International Journal of Pharmacology, 2013, 9, 265-270.	0.1	2
562	Liver transplant patients. , 2013, , 343-357.		0
563	The Pharmacogenomics of Cytochrome P450s: From Molecular to Clinical Application. , 2014, , 345-370.		1
564	Beaned. , 2015, , 693-695.		0
566	Late Transplant Considerations. , 2016, , 1-16.		0
567	A Pilot Study of the Pharmacokinetics of the Modified-Release Once-Daily Tacrolimus Formulation Administered to Living-Donor Liver Transplant Recipients. Experimental and Clinical Transplantation, 2016, 14, 412-8.	0.2	3
568	Interakce mezi mykofenolÃ¡t mofetilem a takrolimem u pacientÅ¯ po transplantaci ledviny. Klinicka Farmakologie A Farmacie, 2017, 31, 3-6.	0.1	1
569	Late Transplant Considerations. , 2018, , 505-520.		0
571	Influence of different formulations of tacrolimus on dosage regimen and drug exposure within the first year after kidney transplantation. Hospital Pharmacology, 2019, 6, 774-784.	0.1	1
572	Conversion From Twice-Daily to Once-Daily Tacrolimus Among Egyptian Living-Donor Kidney Allograft Recipients: A Single-Center Experience. Experimental and Clinical Transplantation, 2019, 17, 594-598.	0.2	1
573	Pharmacogenomics of Immunosuppressants. , 2020, , 83-106.		0

#	Article	IF	Citations
574	Bioequivalence of two tacrolimus 1-mg formulations under fasting conditions in healthy subjects: A randomized, two-period crossover trial. International Journal of Clinical Pharmacology and Therapeutics, 2020, 58, 183-193.	0.3	2
575	Beneficial effects of Wuzhi Capsule on tacrolimus blood concentrations in liver transplant patients with different donorâ€recipient CYP3A5 genotypes. Journal of Clinical Pharmacy and Therapeutics, 2022, 47, 200-210.	0.7	4
576	Towards next-generation personalization of tacrolimus treatment: a review on advanced diagnostic and therapeutic approaches. Pharmacogenomics, 2021, 22, 1151-1175.	0.6	2
577	CYP3A-status is associated with blood concentration and dose-requirement of tacrolimus in heart transplant recipients. Scientific Reports, 2021, 11, 21389.	1.6	8
578	INSIGHT INTO THE POTENTIAL INFLUENCE OF INTER- AND INTRA-INDIVIDUAL VARIABILITY OF TACROLIMUS EXPOSURE ON GRAFT FUNCTION DECLINE IN THREE-YEAR PERIOD FOLLOWING KIDNEY TRANSPLANTATION. Farmacia, 2020, 68, 1036-1046.	0.1	2
580	Assessment of knowledge and practice of Sudanese renal transplant recipients about tacrolimus usage: A cross-sectional study. International Journal of Health & Allied Sciences, 2020, 9, 136.	0.0	0
581	Availability of oral liquid formulations: Dilemmas in managing children with nephrotic syndrome. International Journal of Noncommunicable Diseases, 2020, 5, 194.	0.4	0
582	Monitoring Tacrolimus Concentrations in Whole Blood and Peripheral Blood Mononuclear Cells: Inter- and Intra-Patient Variability in a Cohort of Pediatric Patients. Frontiers in Pharmacology, 2021, 12, 750433.	1.6	4
583	Data-Driven Management of Post-transplant Medications: An Ambiguous Partially Observable Markov Decision Process Approach. Manufacturing and Service Operations Management, 2020, 22, 1066-1087.	2.3	14
584	Monitoring Tacrolimus Trough Concentrations During the First Year After Kidney Transplantation: A National Retrospective Cohort Study. Frontiers in Pharmacology, 2020, 11, 566638.	1.6	7
585	Population pharmacokinetics and pharmacogenomics of tacrolimus in Chinese children receiving a liver transplant: initial dose recommendation. Translational Pediatrics, 2020, 9, 576-586.	0.5	2
586	Efficacy and Safety Evaluation After Conversion From Twice-Daily to Once-Daily Tacrolimus in Stable Liver Transplant Recipients: A Phase 4, Open-Label, Single-Center Study. Transplantation Proceedings, 2021, 53, 3000-3006.	0.3	1
587	Genetic Polymorphisms Affecting Tacrolimus Metabolism and the Relationship to Post-Transplant Outcomes in Kidney Transplant Recipients. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 1463-1474.	0.4	5
588	Variability of Tacrolimus Trough Concentration in Liver Transplant Patients: Which Role of Inflammation?. Pharmaceutics, 2021, 13, 1960.	2.0	2
589	Tacrolimus Induced Organ Failure: Reversal by Activation of the Cytochrome P450-3a System. Uro, 2021, 1, 222-227.	0.3	1
590	Predictive Performance of Published Tacrolimus Population Pharmacokinetic Models in Thai Kidney Transplant Patients. European Journal of Drug Metabolism and Pharmacokinetics, 2022, 47, 105-116.	0.6	1
591	Limited sampling strategies for estimation of tacrolimus exposure in kidney transplant recipients receiving extendedâ€release tacrolimus preparation. Clinical and Translational Science, 2022, 15, 70-78.	1.5	8
592	Comparing weightâ€based dosing of tacrolimus XR in obese and nonâ€obese renal transplant recipients. Clinical Transplantation, 2022, 36, e14529.	0.8	4

#	Article	IF	Citations
593	Bioavailability of onceâ€daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study. Clinical Transplantation, 2022, 36, e14550.	0.8	7
594	Sensitivity of estimated tacrolimus population pharmacokinetic profile to assumed dose timing and absorption in realâ€world data and simulated data. British Journal of Clinical Pharmacology, 2022, 88, 2863-2874.	1.1	1
595	Population pharmacokinetics and pharmacogenomics of tacrolimus in Chinese children receiving a liver transplant: initial dose recommendation. Translational Pediatrics, 2020, 9, 576-586.	0.5	9
596	Microbial Therapeutics in Liver Disease. , 2022, , 271-285.		1
597	Assessment of Tacrolimus Neurotoxicity Measured by Retinal OCT. Transplantation Proceedings, 2022, 54, 80-86.	0.3	2
598	Predicting modelâ€informed precision dosing: A testâ€case in tacrolimus dose adaptation for kidney transplant recipients. CPT: Pharmacometrics and Systems Pharmacology, 2022, , .	1.3	2
600	FK506 and Lactobacillus acidophilus ameliorate acute graft-versus-host disease by modulating the T helper 17/regulatory T-cell balance. Journal of Translational Medicine, 2022, 20, 104.	1.8	8
601	Lessons of the month 2: A case of inappropriate drugâ€“drug interaction in kidney transplant. Clinical Medicine, 2022, 22, 169-171.	0.8	3
602	Model-Based Tacrolimus Follow-up Dosing in Adult Renal Transplant Recipients: A Simulation Trial. Therapeutic Drug Monitoring, 2022, 44, 606-614.	1.0	7
604	The Relationship between Initial Tacrolimus Metabolism Rate and Recipients Body Composition in Kidney Transplantation. Journal of Clinical Medicine, 2021, 10, 5793.	1.0	4
607	Efficacy and outcomes of CYP3A5 genotype-based tacrolimus dosing compared to conventional body weight-based dosing in living donor kidney transplant recipients. Indian Journal of Nephrology, 2022, 32, 240.	0.2	0
608	Effect of Jejunal Administration on Tacrolimus Trough Concentrations in a Pediatric Liver Transplant Recipient. Journal of Pediatric Pharmacology and Therapeutics, 2022, 27, 390-395.	0.3	0
609	The pharmacokinetics of tacrolimus in peripheral blood mononuclear cells and limited sampling strategy for estimation of exposure in renal transplant recipients. European Journal of Clinical Pharmacology, 2022, , .	0.8	1
610	The importance of CYP2C19 genotype in tacrolimus dose optimization when concomitant with voriconazole in heart transplant recipients. British Journal of Clinical Pharmacology, 2022, 88, 4515-4525.	1.1	8
611	Population pharmacokinetics and dosage optimisation of tacrolimus coadministration with Wuzhi capsule in adult liver transplant patients. Xenobiotica, 2022, 52, 274-283.	0.5	2
612	Prolonged-Release Once-Daily Formulation of Tacrolimus Versus Standard-of-Care Tacrolimus in de novo Kidney Transplant Patients Across Europe. Transplant International, 0, 35, .	0.8	9
613	A Prediction Model for Tacrolimus Daily Dose in Kidney Transplant Recipients With Machine Learning and Deep Learning Techniques. Frontiers in Medicine, 0, 9, .	1.2	4
614	Clinical validation of a liquid chromatography-tandem mass spectrometry method for the quantification of calcineurin and mTOR inhibitors in dried matrix on paper discs. Journal of Mass Spectrometry and Advances in the Clinical Lab, 2022, , .	1.3	2

#	Article	IF	Citations
616	Effect of Curcumin at Various Doses on the Pharmacokinetic Profile of Tacrolimus in Healthy Rabbits. Iraqi Journal of Pharmaceutical Sciences, 2022, 31, 246-250.	0.1	0
617	Tacrolimus CYP3A Single-Nucleotide Polymorphisms and Preformed T- and B-Cell Alloimmune Memory Improve Current Pretransplant Rejection-Risk Stratification in Kidney Transplantation. Frontiers in Immunology, 0, 13, .	2.2	0
618	Machine learning-based quantitative prediction of drug exposure in drug-drug interactions using drug label information. Npj Digital Medicine, 2022, 5, .	5.7	12
619	Population Pharmacokinetics and Initial Dosage Optimization of Tacrolimus in Pediatric Hematopoietic Stem Cell Transplant Patients. Frontiers in Pharmacology, 0, 13, .	1.6	2
620	Explainability methods for machine learning systems for multimodal medical datasets. , 2022, , .		1
621	Patterns in Tacrolimus Variability and Association with De Novo Donor-Specific Antibody Formation in Pediatric Kidney Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 1194-1203.	2.2	5
622	Investigation of Therapeutic Drug Monitoring of Tacrolimus in Different Age Groups: Results from a Turkish Nationwide Study. Letters in Drug Design and Discovery, 2022, 19, .	0.4	0
623	Blood, Cellular, and Tissular Calcineurin Inhibitors Pharmacokineticâ€“Pharmacodynamic Relationship in Heart Transplant Recipients: The INTRACAR Study. Therapeutic Drug Monitoring, 2023, 45, 229-235.	1.0	2
624	Tacrolimus toxicity-related chorea in an infant after liver transplantation. Acute and Critical Care, 0, , .	0.6	0
625	Cytochrome P450 oxidoreductase variant A503V contributes to the increased CYP3A5 activity with tacrolimus in vitro. Expert Opinion on Drug Metabolism and Toxicology, 0, , 1-7.	1.5	0
626	The effect of the very low dosage diltiazem on tacrolimus exposure very early after kidney transplantation: a randomized controlled trial. Scientific Reports, 2022, 12, .	1.6	1
627	Sirolimus vs tacrolimus: Which one is the best therapeutic option for patients undergoing liver transplantation for hepatocellular carcinoma?. World Journal of Gastrointestinal Surgery, 2022, 14, 862-866.	0.8	0
628	Genome wide association study identifies a novel variant associated with tacrolimus trough concentration in Chinese renal transplant recipients. Clinical and Translational Science, 0, , .	1.5	2
629	CYP3A4/5 genotypes and age codetermine tacrolimus concentration and dosage in pediatric heart transplant recipients. International Immunopharmacology, 2022, 111, 109164.	1.7	3
630	TLR10 genotypes affect long-term graft function in tacrolimus-treated solid organ transplant recipients. International Immunopharmacology, 2022, 111, 109160.	1.7	1
631	Predicting Tacrolimus Exposure in Kidney Transplanted Patients Using Machine Learning. , 2022, , .		2
633	Impact of Tacrolimus Trough Variability on Acute Rejection Following Lung Transplantation. Transplantation Proceedings, 2022, 54, 2270-2270.	0.3	1
634	Hexafluoroisopropanol for the Selective Deactivation of Poisonous Nucleophiles Enabling Catalytic Asymmetric Cyclopropanation of Complex Molecules. ACS Catalysis, 2022, 12, 12530-12542.	5.5	7

#	Article	IF	Citations
635	Population Pharmacokinetics of Tacrolimus in Pediatric Patients With Umbilical Cord Blood Transplant. Journal of Clinical Pharmacology, 2023, 63, 298-306.	1.0	0
636	Strong influence of donor and recipient CYP3A5 genotype on tacrolimus disposition leading to difficult dose adjustment in a pediatric liver transplantation. Journal of Liver Transplantation, 2022, 8, 100132.	0.2	1
637	Therapeutic Drug Monitoring and Toxicology of Immunosuppressant. , 2022, , 181-196.		0
638	Comparison of Tacrolimus Intra-Patient Variability during 6â€“12 Months after Kidney Transplantation between CYP3A5 Expressers and Nonexpressers. Journal of Clinical Medicine, 2022, 11, 6320.	1.0	5
639	Controversial Interactions of Tacrolimus with Dietary Supplements, Herbs and Food. Pharmaceutics, 2022, 14, 2154.	2.0	5
640	GRWR Correlates with the Metabolism of Tacrolimus after Pediatric Living Donor Liver Transplantation According to Donor CYP3A5 Polymorphism. BioMed Research International, 2022, 2022, 1-15.	0.9	0
641	Comparative Study of 2 Extended-Release Tacrolimus Formulations in Kidney Transplantation. Transplantation Proceedings, 2022, 54, 2434-2438.	0.3	0
642	Prospective population pharmacokinetic study of tacrolimus in adult recipients early after liver transplantation: A comparison of Michaelis-Menten and theory-based pharmacokinetic models. Frontiers in Pharmacology, 0, 13, .	1.6	1
643	Optimization of the precursor supply for an enhanced FK506 production in Streptomyces tsukubaensis. Frontiers in Bioengineering and Biotechnology, 0, 10, .	2.0	5
644	Genotype-guided model significantly improves accuracy of tacrolimus initial dosing after liver transplantation. EClinicalMedicine, 2023, 55, 101752.	3.2	2
645	Effect of Wuzhi preparations on tacrolimus in CYP3A5 expressers during the early period after transplantation: A real-life experience from heart transplant recipients. Transplant Immunology, 2023, 76, 101748.	0.6	1
646	Optimizing Dosing Regimens of Tacrolimus in Lung Transplant Recipients. , 2022, , .		0
647	Monitoring of blood immunosuppressant concentrations and lymphocyte activation for predicting viral infections following kidney transplantation: A pilot study. Medicine (United States), 2022, 101, e31783.	0.4	0
648	The effect of tacrolimus-induced toxicity on metabolic profiling in target tissues of mice. BMC Pharmacology & Toxicology, 2022, 23, .	1.0	3
649	Renal Function, Adherence and Quality of Life Improvement After Conversion From Immediate to Prolonged-Release Tacrolimus in Liver Transplantation: Prospective Ten-Year Follow-Up Study. Transplant International, 0, 35, .	0.8	1
651	Application of machine learning to predict tacrolimus exposure in liver and kidney transplant patients given the MeltDose formulation. European Journal of Clinical Pharmacology, 2023, 79, 311-319.	0.8	3
652	Differences in medication adherence by sex and organ type among adolescent and young adult solid organ transplant recipients. Pediatric Transplantation, 0, , .	0.5	3
653	Population Pharmacokinetic Analysis for Model-Based Therapeutic Drug Monitoring of Tacrolimus in Chinese Han Heart Transplant Patients. European Journal of Drug Metabolism and Pharmacokinetics, 0, , .	0.6	1

#	Article	IF	Citations
654	Model-Informed Estimation of Acutely Decreased Tacrolimus Clearance and Subsequent Dose Individualization in a Pediatric Renal Transplant Patient With Posterior Reversible Encephalopathy Syndrome. Therapeutic Drug Monitoring, 2023, Publish Ahead of Print, .	1.0	0
655	Factors Affecting Day-to-Day Variations in Tacrolimus Concentration among Children and Young Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy, 2023, 29, 270.e1-270.e8.	0.6	0
656	Tacrolimus induces fibroblast-to-myofibroblast transition via a TGF-Î²-dependent mechanism to contribute to renal fibrosis. American Journal of Physiology - Renal Physiology, 2023, 324, F433-F445.	1.3	2
657	Comparison between monoâ€tacrolimus and monoâ€glucocorticoid in the treatment of myasthenia gravis. Annals of Clinical and Translational Neurology, 2023, 10, 589-598.	1.7	0
658	Impact of CYP3A5 genotype on de-novo LCP tacrolimus dosing and monitoring in kidney transplantation. Pharmacogenetics and Genomics, 2023, 33, 59-65.	0.7	0
659	Evaluation of limited-sampling strategies to calculate AUC(0â€“24) and the role of CYP3A5 in Chilean pediatric kidney recipients using extended-release tacrolimus. Frontiers in Pharmacology, 0, 14, .	1.6	0
662	Pharmacogenomics and beyond! Customized pharmacotherapy for solid organ transplant recipients. Pharmacotherapy, 2023, 43, 596-608.	1.2	2
663	Pharmacokinetic Evaluation of Tacrolimus in Chinese Adult Patients during the Early Stages Post-Lung Transplantation. Journal of Personalized Medicine, 2023, 13, 656.	1.1	1
664	Potential profound fluctuation in tacrolimus concentration on consumption of pomegranate rind extract: A Pharmacokinetic Experiment. Frontiers in Pharmacology, 0, 14, .	1.6	0
665	Increased Tacrolimus Exposure in Kidney Transplant Recipients With COVID-19: Inflammation-Driven Downregulation of Metabolism as a Potential Mechanism. Transplant International, 0, 35, .	0.8	3
666	Pharmacogenetics and toxicology. , 2024, , 467-491.		0
700	Pharmacogenomics on Immunosuppressive Drugs in Solid Organ Transplantation. , 2023, , 263-270.		0
706	Synthetic Activators of Autophagy. Biochemistry (Moscow), 2024, 89, 27-52.	0.7	1